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ABSTRACT

MECHANISTIC INSIGHT OF THE ROLE OF NHERF1 IN CISPLATIN-INDUCED
ACUTE KIDNEY INJURY
Adrienne M. Bushau-Sprinkle
January 22, 2020

Background. Acute kidney injury (AKI) develops in 30% of patients who receive
cisplatin, a widely used chemotherapeutic agent. We previously showed that
NHERF1 loss resulted in increased susceptibility to cisplatin nephrotoxicity. The
overarching goal of this dissertation was to elucidate mechanisms of
susceptibility to cisplatin-induced AKI, specifically the effects of NHERF1 loss on
tubule cell metabolism, tubule cell mitochondrial function, and alterations in
oxidative state and/or renal handling of cisplatin. Methods. 2-4 month male wild
type (WT) and NHERF1 knock out (KO) mice were treated with either vehicle
control or cisplatin (20 mg/kg dose IP) for 4, 24, and 72 hours. Urine was
collected for NGAL and kidneys were harvested for histology and the following
assays: Thiobarbituric Acid Reactive Substances (TBARS) for lipid peroxidation,
γ-glutamyl transferase (GGT) activity, and Western Blot for GGT and cysteine Sconjugate beta lyase (CCBL). Mitochondrial respiration was conducted via the
Seahorse XF24 analyzer on non-treated isolated kidney mitochondria. LC-MS
vi

analysis was used to evaluate ATP content in non-treated kidneys. Electron
microscopy was utilized to evaluate mitochondrial morphology and number in
non-treated kidneys. HPLC of the reduced and oxidized forms of the small
molecular weight thiols (glutathione (GSH), glutathione disulfide (GSSG),
cysteine (Cys), and cystine (CySS), and cysteine-glutathione disulfide (CySSG)
on plasma and kidney cortex. Statistical analysis was completed using Student’s
t-test for LC-MS, mitochondrial number, and mitochondrial respiration and Twoway ANOVA was used for all other analysis. P-values of <0.05 were considered
statistically significant. Results. Chapter III demonstrates that WT and NHERF1
KO mice do not exhibit metabolic changes or changes in ATP content that would
definitively sensitize the KO mice to cisplatin injury. Chapter IV shows that
NHERF1 loss does not affect mitochondrial morphology or mitochondrial number,
or oxidative phosphorylation capacity via Seahorse XF24 analysis. Thus,
mitochondrial dysfunction does not appear to sensitize the KO mice to cisplatin
injury. Lastly, Chapter V reveals that NHERF1 KO mouse kidneys do not exhibit
changes in lipid peroxidation, oxidative stress, GGT or CCBL protein levels that
would sensitize these animals to cisplatin. However, NHERF1 KO kidneys
appear to respond differently to the cisplatin insult itself, characterized by
differences in GGT activity in response to cisplatin. Conclusions. In conclusion,
the work presented in this dissertation reveals that metabolic stress and
mitochondrial dysfunction are not the mechanisms of susceptibility to cisplatin in
NHERF1 KO mice. Furthermore, NHERF1 loss does not lead to changes in
kidney GSH metabolism. In conclusion, these data do not support NHERF1 loss

vii

resulting in a fundamental metabolic defect that increases susceptibility to
cisplatin injury. Instead NHERF1 loss appears to influence either the handling,
the initial insult, or the response to injury resulting in exacerbated injury.
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CHAPTER I

INTRODUCTION

A.

Background and rationale for this study

1. Structure and function of the kidney
In humans and in most mammals the normal kidney is bean shaped and
found in pairs within the abdominal cavity behind the peritoneum (1, 2). Each
kidney is covered by a fibrous capsule with a slit located in the central concave
portion of the kidney called the hilum (1, 2) (Figure 1.1). The hilum serves as
both the entry site for the renal artery and the exit site of the renal vein (1, 2). The
hilum opens into the renal sinus, composed of shallow urine-filled spaces (1, 2).
Once bisected the kidney is composed of 3 main regions, the cortex, the outer
medulla, and the inner medulla (1, 2) (Figure 1.1). The cortex is comprised of
glomeruli (clumps of capillaries) and tubules (convoluted epithelial structures),
while the medulla lacks glomeruli and consists of parallel arrangements of
tubules (1, 2).
The nephron is the functional unit of the kidney and it consists of a
glomerulus and a tubule (Figure 1.2). The glomerulus is a group of blood vessels
that forms filtrate from blood plasma, while the epithelial tubule is designed to
1

Figure 1.1

Figure 1.1: Structure of the mammalian kidney.
The kidney structure includes three regions: an outer cortex, outer medulla, and
inner medulla. The arteries and veins that support the kidney enter and exit at the
hilum. Additionally, the hilum serves as a point of exit for the ureter.

2

Figure 1.2

Figure 1.2: Structure of the nephron.
The nephron is the functional unit of the kidney and is responsible for removing
wastes. Both the glomerulus and the sections of the tubules of the nephron are in
the cortex of the kidney.

3

convert the blood plasma filtrate into urine (1, 2). Bowman’s capsule surrounds
the glomerulus and the site where the filtrate passes from the vascular to the
tubule system (1, 2). The epithelial tubule is divided into multiple subdivisions
called the proximal tubule, the thin descending and ascending limb of the loop of
Henle, the thick ascending limb of the loop of Henle, the distal convoluted tubule,
and the collecting tubule (2) (Figure 1.2). The tubules of the kidney are
instrumental in recovery of most of the fluid and solutes filtered from the
glomerulus (1).
The proximal tubule recovers the vast majority of filtrate from the
glomerulus and is involved in regulating acid-base balance (2), salt and water
homeostasis, recovery of filtered glucose and amino acids, as well as divalent ion
metabolism (1, 2). Additionally, the proximal tubule is the site for organic anion
and cation transport, including drugs. The loop of Henle creates the conditions
required for the generation of a concentrated or dilute urine, by pumping salts
and urea into the medulla to establish the progressively hypertonic cortical to
medullary gradient within the renal interstitium (1, 2). The creation of this osmotic
gradient enables the regulated movement of water from tubule to interstitium,
thus determining urine osmolality. The distal tubule and collecting duct system
are sites for more precise control of water and salt excretion via several
hormones (e.g., aldosterone, arginine vasopressin) (1, 2). All of these structures
collectively enable the kidney to form a filtrate of blood plasma and to selectively
reabsorb the tubule fluid or secrete solutes into it.

4

2. Importance of the kidney in human health and disease
The kidneys are multifunctional organs involved in maintaining blood volume,
total body salt and water balance, acid-base balance, and bone strength and
integrity (1). The kidneys accomplish these tasks through cooperation with other
organ systems. Each of these tasks are important in human health, and
disruption of one or more of these functions can result in complications and/or
the development of disease (1, 3).
The human body intakes water, salt, and electrolytes at varying degrees that
can interrupt the body’s balance of these substances. The kidneys have the
ability to vary their excretion of electrolytes and water to maintain this balance (1,
3). Another aspect of this balance of water, salts, and electrolytes is the
regulation of plasma osmolality, the combined concentration of these substances
(1, 3). Osmolality is altered whenever the input and output of water and solutes
shift disproportionally (2, 3). Thus, the kidneys must excrete water and solutes to
match the intakes at rates that maintain the ratio of solutes and water close to a
constant value of 292 milliosmoles per kilogram (mOsm/kg) (2, 3). In addition to
excreting excess amounts of substances the kidney also responds to shortages.
To accomplish this response the kidneys will reduce the output leading to the
restoration of this balance of water and solutes (1, 3). One of the major actions of
the kidney is to regulate all of the electrolytes, body water, and plasma osmolality
independently (2, 3).
The kidneys work in tandem with other organ systems including the
cardiovascular system (1, 2). The kidneys regulate systemic blood pressure by:
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[1] determining blood volume which controls cardiac output (heart rate x stroke
volume); and [2] producing hormones that regulate vascular resistance (systemic
blood pressure/cardiac output) (2, 3). It is vital that the kidneys maintain
extracellular fluid volume, which includes blood plasma (1-3). This maintenance
ensures that there is sufficient volume to fill the vascular space, allowing blood to
circulate normally (1-3). Maintenance of the extracellular fluid volume is a result
of the kidneys’ regulation of water and salt balance (2, 3). In addition to
maintaining adequate volume of the cardiovascular system, the kidneys produce
vasoactive substances (e.g., renin-angiotensin-aldosterone system) that help
control vascular smooth muscle (2, 3). This influences peripheral vascular
resistance and consequently systemic arterial blood pressure (1-3). Disruption of
this aspect of renal function leads to the development of hypertension (1, 3).
The human body constantly forms the end products of metabolic processes,
which must be excreted at the same rate that they are produced (1, 2). These
products include urea from protein, uric acid from nucleic acids, creatinine from
muscle creatinine, urobilin from hemoglobin breakdown, and the metabolites of
various hormones and biochemical processes (2, 3). Collectively these products
are called uremic toxins when they accumulate under conditions of kidney failure
(3), and contribute to uremia, the constellation of clinical features characteristic of
advanced chronic kidney disease (CKD) (1, 3). In addition, the kidneys are
responsible for the excretion of many types of drugs. Frequently these drugs
damage the kidneys leading to alterations in kidney function.
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Although the kidneys are responsible for excretion of hormones and their
metabolites, they are also involved in production of the hormone erythropoietin
(1-3). Interstitial cells located in the cortical intersititum (border between renal
cortex and medulla) secrete this hormone that stimulates the production of red
blood cells in the bone marrow (1, 2). The reduction of partial oxygen pressure
stimulates the kidney cells to secrete erythropoietin (2, 3). In cases of anemia,
blood loss, or insufficient blood flow to the kidneys the local oxygenation drops
and triggers secretion of erythropoietin (1-3).
The kidneys in combination with the gastrointestinal (GI) tract are essential
regulators for phosphate and calcium homeostasis, which is necessary for bone
health (1-3). The kidneys accomplish this homeostasis through the production of
calcitriol (active form of vitamin D) (1-3). Calcitriol helps increase calcium
absorption from the intestine into the blood. CKD can disrupt this process and
cause a form of bone disease, renal osteodystrophy (1, 3). Moreover, the
impaired bone metabolism is accompanied by calcium-phosphate deposits in
blood vessels, increasing the risk of heart disease (3).
Lastly, the kidneys are responsible for maintaining tight control of acid-base
balance and they are a site of gluconeogenesis (body’s process of producing
glucose from non-carbon sources) (1-3). Disruption in acid-base balance can
lead to life-threatening conditions such as metabolic acidosis and alkalosis (1-3).
Loss of gluconeogenesis can result in hypoglycemia in advanced CKD,
particularly under conditions of stress or nutrient deficiency.
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Altogether the kidney is a unique organ that is involved in many vital
processes. The kidneys excrete many substances and help maintain the body’s
homeostasis. Equally important to the kidneys’ ability to excrete waste, the
kidneys also work in partnership with other organ systems through production of
hormones. Consequently, alterations in any of these processes can lead to
complications and the development of disease in the body, further illustrating the
importance of the normal functioning kidney to overall human health.

3. Acute kidney injury
Acute kidney injury (AKI) is defined as an abrupt decline in kidney function,
and is a common clinical condition; approximately 20% of all hospital admissions
are related to AKI (4). 2-300 per million cases of AKI are severe enough to
require dialysis (5). Meanwhile, 2-3000 per million cases of AKI do not require
dialysis (5). In the critical care setting close to two thirds of patients will develop
AKI and around five percent of intensive care unit (ICU) patients will develop
severe cases of AKI that warrant dialysis (5). AKI is associated with a four-fold
increase in mortality and is a risk factor for the development of CKD (5).
AKI can be divided into three pathophysiological categories: pre-renal,
intrinsic, and post-renal (obstructive) (2). Pre-renal AKI results from a decrease in
arterial blood volume leading to kidney hyperfusion (2), but without intrinsic
damage to the kidney tissue. Hemorrhage from trauma or surgery, septic shock,
and cirrhosis are all conditions that can lead to the development of pre-renal AKI
(2). Intrinsic AKI occurs from direct damage to the kidneys resulting in a sudden
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loss in kidney function. The common causes are acute tubular necrosis (ATN),
acute glomerulonephritis (AGN), and acute interstitial nephritis (AIN) (2).
Ischemic and septic ATN are the most common causes of intrinsic AKI, however,
ATN can result from drug toxicities (2). AGN can be the result of autoimmune
diseases, such as Lupus Nephritis, which can damage and inflame the glomeruli
of the kidneys (2). AIN manifests as severe inflammation of the kidneys. This
inflammation is usually the result of medications, such as antibiotics or a
nonsteroidal anti-inflammatory drugs (NSAIDs) such as naproxen or ibuprofen
(2). Additionally, AIN can be caused by streptococcal, viral, or Legionella
infection (2). Post-renal AKI is commonly induced by the obstruction of the
ureters, bladder outlet, or urethra (2). These obstructions may be due to prostatic
conditions, anticholinergic agent therapy, blood clots, or ureter fibrosis (2). From
herein the focus of this dissertation will focus on drug-induced intrinsic AKI.
Drugs are the third to fifth leading cause of AKI in critically ill patients (6)
consistent with the kidneys’ role in concentrating and excreting toxic metabolites
and drugs (7), making them a common site of drug toxicity. Drugs damage the
kidneys by several mechanisms: [1] vasoconstriction, [2] altered intraglomerular
hemodynamics, [3] tubular cell toxicity, [4] interstitial nephritis, [5] crystal
deposition, [6] drug-induced thrombotic microangiopathy, [7] osmotic nephrosis,
and [9] rhabdomyolysis.
Vasoconstriction is the mechanism of nephrotoxicity of calcineurin inhibitors,
vasopressors, and contrast agents (7). The use of NSAIDs, angiotensin
converting enzyme inhibitors (ACEI), and angiotensin receptor blockers (ARB)
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can lead to altered intraglomerular hemodynamics resulting in a decline in kidney
function (7). The proximal tubule is particularly vulnerable to toxic injury due to its
role of reabsorbing the glomerular filtrate. Tubular cell toxicity is seen in a dosedependent manner for many drugs (e.g. aminoglycosides, amphotericin,
calcineurin inhibitors, cisplatin, methotrexate, and antivirals) causing kidney injury
(7), while crystal deposition in the distal tubular lumen is pH-dependent and
commonly seen in nephrotoxicity associated with acyclovir, sulfonamide,
methotrexate, indinavir, and triamterene (7). Additionally, uric acid and calcium
phosphate crystals are observed following chemotherapy (7). Drug-induced
thrombotic microangiopathy has been reported with mitomycin, cyclosporin,
tacrolimus, interferon, and quinine (7). Osmotic nephrosis has been associated
with high doses of mannitol and immunoglobulins (7) and results from
hyperoncotic solutions by decreasing glomerular filtration rate (GFR) or from
osmotically induced tubular damage (7).
Unfortunately, the need for many of these medications outweighs the risk of
nephrotoxicity development. During these instances measures are taken to
minimize the drug-induced kidney damage, but these measures are not always
successful. For these reasons innovative and novel research is needed toward
the prevention of drug-induced AKI.

4. History of cisplatin in the clinic
Cisplatin is a widely used chemotherapeutic to treat a variety of solid
malignant tumors (e.g. head and neck, ovarian, testicular, and lung cancer) (8).
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As discussed previously, cisplatin is associated with proximal tubule toxicity in
AKI. To fully understand cisplatin’s efficacy in the clinic despite its toxicity, it is
important to also understand its development and long history of use clinically.
The biological effects of platinum were discovered in 1961 by a physicist,
Barnett Rosenberg, while examining if alternating electromagnetic forces could
affect cell division (9). Rosenberg set up platinum conducting plates in a chamber
with Escherichia coli (E. coli) grown on a medium containing ammonium chloride,
which provided the nitrogen required for cell growth (9). Rosenberg then applied
an electric current and observed that the E. coli stopped dividing (9). He carried
out further experiments to determine what was inhibiting the cell division, and
discovered it was the platinum when combined with ammonia molecules (9). This
discovery led to the further development of using platinum complexes as antitumor agents. A number of platinum complexes were tested, however, only the “cis” complexes with adjacent ammonia groups displayed anti-tumor activity (9). In
1969 the cisplatin (cis-diammine-dichloroplatinum (II)) compound was discovered
to have the most potent anti-tumor effects (9). Cisplatin has a central platinum
atom bound by ammonia and chloride groups in a square planar structure (10)
(Figure 1.3). Cisplatin forms DNA crosslinks which interrupt cellular DNA
functioning and induces apoptosis (10). This is accomplished through the two
“leaving” chloride groups which readily dissociate in physiological conditions, and
the subsequent formation of a platinum-DNA adducts that can only be repaired
using nucleotide excision repair (10).
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Figure 1.3

Figure 1.3: Structure of cis-diamminedichloroplatinum (II) or cisplatin.
Molecular structure of cisplatin is a square planar complex with two labile
chlorine and two inert ammonia molecules that are coordinated to the central
platinum (II) atom in the cis configuration.
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Following pre-clinical and human studies cisplatin was approved by the Food
and Drug Administration (FDA) in 1978 for the treatment of advanced metastatic
testicular, ovarian and bladder cancer (11). Since then it has had great success
as a chemotherapeutic agent and is one of the most widely used anti-tumor
drugs in the world. For example, in the early 1970s metastatic testicular cancer
was associated with a 5% survival rate (12). Improved surgical techniques in
combination with cisplatin chemotherapy has increased the 5-year survival rate
for men with testicular cancer to 95% (12). Furthermore, as recently as 2010
there were over 500 active clinical trials involving cisplatin (13), underlying its
continued prominent use in the treatment of solid malignant tumors.
Unfortunately, the major limiting factor of cisplatin is its nephrotoxicity.
The first report of cisplatin’s nephrotoxicity was in 1971 during pre-clinical
animal studies (13). These studies found histopathologic changes of ATN along
with azotemia (abnormally high levels of nitrogen containing compounds in the
blood). Early clinical use of cisplatin saw dose-related renal failure in 14-100% of
patients, with the incidence varying with the cumulative dose (13). This high
severity of toxicity almost prevented cisplatin’s FDA approval as a
chemotherapeutic agent (8, 14). In response, hydration protocols were
developed that reduced the nephrotoxicity and allowed the implementation of
increased doses to reach therapeutic levels (8, 15). Subsequently, cisplatin alone
and in combination based chemotherapy regimens are currently used as a frontline therapy for testicular cancer, ovarian germ cell tumors, epithelial ovarian
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cancer, head and neck cancer, advanced cervical cancer, bladder cancer,
mesothelioma, endometrial cancer, non-small cell lung cancer, malignant
melanoma, carcinoids, penile cancer, and adrenocortical carcinoma (8).
Additionally, it is used as a consolidation therapy for many types of solid tumors
that have failed standard treatment regimens (8). Even though cisplatin is widely
used, and hydration protocols decreased the incidences of kidney injury, cisplatin
is still associated with a risk of 20-30% of patients developing AKI after a single
dose. Research has been ongoing to both understand how cisplatin damages the
kidney and to discover preventative methods.

5. Cisplatin and the kidney
Nephrotoxicity is an unusual side effect of a chemotherapeutic agent in
general. In most cases chemotherapy drugs target pathways that are essential
for cell division and therefore rapidly dividing cells such as bone marrow cells are
most sensitive to these agents. Thus, the high rate of nephrotoxicity in the kidney
which as a low cell turnover rate is unexpected and indicates that cisplatin may
have two distinct mechanisms that kill cells, one for highly prolific cancer cells
and one for quiescent kidney cells.
Cisplatin is cleared by the kidney via glomerular filtration and tubular
secretion (13, 16). Concentration of cisplatin is higher in the kidney than in the
blood suggesting there is active accumulation of the drug by renal parenchymal
cells (8, 13). Even though cisplatin was developed over 50 years ago, its
mechanism of toxicity is not completely understood. Previous studies provided
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evidence that cisplatin undergoes a basolateral-to-apical transport within the
kidney (13, 17). In more recent years studies have identified two membrane
transporters that are capable of cisplatin uptake: copper transporter 1 (Ctr1) and
organic cation transporter 2 (OCT2) (13). Both Ctr1 and OCT2 are highly
expressed in the kidney and found in the basolateral membrane of the proximal
tubule (Figure 1.4). Downregulation of Ctr1 protein expression in kidney cells
decreases cisplatin uptake within the kidney (13, 18). Likewise, OCT2 knock out
(KO) mice demonstrate significantly reduced cisplatin urinary excretion and
nephrotoxicity (13, 19, 20). Furthermore cimetidine, an OCT2 substrate, also
reduced cisplatin uptake and cytotoxicity in vitro (18, 21), and patients with a
nonsynonymous single-nucleotide polymorphism (SNP) in the OCT2 gene
(rs316019) demonstrated a reduced cisplatin-induced nephrotoxicity (13, 19, 20).
Another membrane protein, the multidrug and toxin extrusion 1 (MATE1) protein,
is responsible for cisplatin extrusion out of the proximal tubule into the tubular
lumen (Figure 1.4). MATE1 KO mice also exhibited enhanced cisplatin
nephrotoxicity (22). Taken together these studies suggest that the cell
mechanisms for cisplatin transport in the proximal tubule play a critical role in
determining the susceptibility to injury. In addition to renal cisplatin uptake, there
is evidence that cisplatin undergoes a biotransformation to a more potent toxin in
the kidney (Figure 1.4). Studies in rats and mice show that the process may
begin with the formation of glutathione-conjugates in the circulation, possibly
mediated by glutathione-S-transferase (13, 23, 24). In the kidney these
glutathione-conjugates are extruded by MATE1 and further cleaved to cysteinyl-
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Figure 1.4

Figure 1.4: Cisplatin metabolism to a nephrotoxin.
Cisplatin enters the renal proximal tubule cell and is conjugated to glutathione
(GSH). MATE-1 is responsible for exodus of cisplatin and cisplatin-glutathione
conjugates into the tubule lumen. γ-glutamyl transpeptidase (GGT) and
aminodipeptidase (AP) further metabolize cisplatin-glutathione conjugates to
cisplatin-cysteinyl and cysteine conjugates. The cisplatin-cysteine conjugate reenters the renal proximal tubule cell and cysteine-S-conjugate beta-lyase
metabolizes it to an unstable and reactive cisplatin-thiol conjugate, the
nephrotoxic metabolite of cisplatin.
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glycine-conjugates by γ-glutamyl transpeptidase (GGT) (Figure 1.4), expressed
apically in the proximal tubule (13, 25, 26). The cysteinyl-glycine-conjugates are
further metabolized to cysteine-conjugates by aminopeptidases (AP) (Figure 1.4),
also expressed apically (13, 25, 26). The cysteine-conjugates are transported
back into the proximal tubule by an unknown protein transporter where they are
further metabolized by cysteine-S-conjugate beta lyase (CCBL), forming a highly
reactive thiol (13, 25-27) (Figure 1.4). This reactive thiol is what is believed to
cause the toxicity. Experiments show that blocking any of these enzymes
ameliorates cisplatin nephrotoxicity.
Renal tissue damage, characterized by tubular cell death, is a frequent and
common occurrence of cisplatin nephrotoxicity. Subsequently renal tubule cell
death may be in the form of apoptosis and necrosis. Necrotic cell death has been
observed with high concentrations of cisplatin, whereas lower concentrations led
to apoptosis in vitro (12, 28). In animal models both apoptosis and necrosis can
be observed following cisplatin administration (12, 29). Although there has been
a great deal of investigation into the mechanism of cisplatin-induced
nephrotoxicity there are still many unanswered questions. As a result, it is still not
understood why some patients are more susceptible to cisplatin nephrotoxicity.
To develop either renoprotective strategies or therapies more research is needed
regarding mechanisms of susceptibility along with identifying novel targets that
do not affect cisplatin’s efficacy. One such target recently discussed is the Na/H
exchange regulatory factor 1 (NHERF1) scaffolding protein.
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6. NHERF1: is it more than an anchor?
Cells communicate through coordinated signaling networks that rely on
scaffolding proteins, which organize multiprotein complexes and enable proper
transmission of information. NHERF1 is a member of a post-synaptic density
protein 95/Drosophila Discs Large/Zonula Occulens -1 (PSD-95/DIg/ZO-1)
homology (PDZ) scaffolding protein family. NHERF1 has two tandem PDZ
domains, a carboxy terminal ezrin binding domain, and a CRAC (cholesterol
binding) domain. Initially NHERF1 was identified (30) as an organizer and
regulator of hormone receptors, signal transduction pathways, and transporters
through its interaction with actin-binding-ezrin-radixin-moesin (ERM) proteins on
the apical side of epithelial cells (31, 32). NHERF1 has many known functions in
the kidney including: regulating the sodium hydrogen antiporter 3 (NHE3)
function via the parathyroid hormone (PTH), regulating and anchoring the sodium
phosphate co-transporter type-2 (Npt2a) expression by PTH and dopamine, and
regulating the sodium pump. More recently NHERF1 has been found to be
involved in a variety of functions across multiple cell types including: cell
structure and trafficking, tumorigenesis and tumor behavior (33, 34),
inflammatory responses (2, 18), and tissue injury (35-37). There have been a
number of divergent and contradictory reported effects of NHERF1, making it
difficult to predict how either the absence or the overexpression of NHERF1 will
affect a specific cell function.
Cell Structure
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NHERF1 plays a role in actin cytoskeleton organization (38), cell polarity (39),
and trafficking (40) possibly though its ability to scaffold signaling complexes via
its interaction with ERM proteins. NHERF1 disrupts the actin skeleton in HeLa
cells, thought to be through increased α actinin IV ubiquitination and degradation
(38); however, in Madin-Darby-canine-kidney (MDCK) cells NHERF1 enhances
actin skeleton organization (41) stimulated by podocalyxin-induced RhoA
activation through the Rho/Rho-associated coiled-coil protein kinase (ROCK)
pathway (42).
There are multiple functional consequences of the actin cytoskeleton
organizational role of NHERF1. NHERF1 colocalization with proteins has been
implicated in cell polarity through tight junction formations (39) and protein
targeting to the apical or basolateral membrane (43-45). NHERF1 has a
significant role in protein anchoring and assembly of multi-protein complexes. For
example, NHERF1 expression is critical for assembling G-protein-coupled
receptors (GPCRs), downstream signaling molecules (e.g. adenylyl cyclase), and
target proteins such as Npt2a and the NHE3 in the proximal tubule. Additionally,
NHERF1 is essential for regulating total body phosphate homeostasis by
anchoring Npt2a through ezrin binding and subsequently the NHERF1 KO
mouse displays phosphaturia and uricosuria (46).
In addition to membrane targeting NHERF1 may also play a role in
establishing cell phenotype. NHERF1 mediated plasma membrane expression of
the calcium adenosine triphosphatase (Ca-ATPase) 2 prevented involution of
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lactating mammary gland cells through suppression of the signal transducer and
activator of transcription 3 (Stat3) activation (43).
Cancer
NHERF1 exhibits a dual role in tumorigenesis that is dependent on its
expression or subcellular localization. When NHERF1 is located at the plasma
membrane it acts as a tumor suppressor (47). In contrast, NHERF1 expression
loss, cytoplasmic or nucleus localization results in pro-oncogenic properties (47).
This phenomenon has been observed in melanoma (48), breast (49-54),
reproductive system (55-58), digestive system (59-63), liver (64-66), lung (67),
and brain cancers (68-71). Potential mechanisms for the effect of NHERF1 on
tumor behavior include: inhibition of the epidermal growth factor receptor (EGFR)
signaling due to a decreased interaction with NHERF1 (72), increased
cytoplasmic expression of vascular endothelial growth factor (VEGF) and its
receptor VEGFR1 (73), alteration in mineral metalloproteinase expression (74),
and enhanced Wnt1 signaling (75). Furthermore, NHERF1 overexpression has
been linked in liver cancer cells, regulation of cell cycle (45, 76, 77), and
suppression of reactive oxygen species (ROS) (78).
Cytoplasmic localization of NHERF1 has been implicated in the development
of metastatic cancers (79). A potential mechanism may involve differential
phosphorylation of NHERF1, where NHERF1 creates protein complexes which
either activate or inactivate the promotion of metastatic behavior (80). For
instance, overexpression of NHERF1 has been associated with pro-metastatic
behavior in breast cancer cell lines. Moreover, overexpression of NHERF1 was
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connected with enhanced cell functions associated with the metastatic phenotype
and mitigated by mutations of the phosphorylation sites S279 or S301 in
NHERF1. NHERF1 phosphorylation is also essential for tumor-induced
angiogenesis (80).
Inflammation and fibrosis
ROS impacts aging/fibrosis, cancer, neurodegenerative disorders, and
cardiovascular disease (81). Interestingly, NHERF1 has been found to be a
binding partner and regulator of NADPH oxidase (Nox1) by directly associating
with the Nox organizing subunit p47phox. Additionally, NHERF1 interacts with
other proteins involved in inflammatory pathways including the interleukin 8 (IL8)
receptor beta, C-X-C Motif light-chain-enhancer of activated B cells (NF-B), and
simultaneously increased NF-B production.
A study using a rat aging model found NHERF1 expression loss was
associated with renal fibrosis development (84). One potential mechanism is
suggested by the observation that NHERF1 blunted the transforming growth
factor beta 1 (TGF-β1) expression of mesenchymal cell markers in a lung cancer
cell line (85). Additionally, a role for NHERF1 in regulating epithelialmesenchymal transition (EMT) is another possibility in lieu of previously cited
studies where NHERF1 plays a role in cell polarity, cell phenotype expression,
and cell cycle regulation.
Response to injury
NHERF1 expression has been implicated in responses to injury. In a model of
cholestatic liver injury induced by bile duct ligation the NHERF1 KO mouse
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exhibits attenuated liver injury (36). Loss of NHERF1 also resulted in the deletion
of the ICAM-1-ERM-NHERF1 complex resulting in a reduction in both hepatic
ICAM1 and ERM proteins, which are essential for neutrophil mediated cholestatic
liver injury (36). Therefore, NHERF1 may have a sensitizing role in inflammatory
induced liver injury. On the other hand, NHERF1 loss does not result in
protection against cisplatin-induced AKI. In fact NHERF1 KO mouse kidneys
were more susceptible to cisplatin-induced AKI (35), exhibiting a decrease in
renal function, a significant increase in urine neutrophil gelatinase-associated
lipocalin (NGAL), and severe histologic damage (casts, BBM sloughing, and
ATN) when compared to cisplatin treated wild type (WT) mice.
Interestingly the absence of NHERF1 protected against liver tissue injury in
the biliary ligation model, but increased sensitivity to injury in the cisplatininduced AKI model. Thus, NHERF1 may have a significant role in the severity of
injury after specific insults and in specific tissues potentially due to regulation of
the acute inflammatory response.
Implications for renal physiology/pathophysiology
NHERF1 has a much broader role than as a scaffold or anchor in the cell,
illustrated by the effect NHERF1 has on a variety of diseases and tissues along
with its contributions to cell growth and proliferation, cell polarity and structure,
determination of cell phenotype, response to inflammation, and neoplastic
transformation. For this dissertation the role NHERF1 plays in susceptibility to
cisplatin-induced AKI (35) will be further investigated. However, many questions
remain including: whether NHERF1 is a primary mediator or responder of kidney
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injury and if NHERF1 can be used as a biomarker or therapeutic target for the
prevention of kidney injury.

7. Metabolism and susceptibility to cisplatin toxicity
As previously discussed, the accumulation and bioactivation of cisplatin to a
more potent nephrotoxic metabolite underlies the kidney’s susceptibility to
cisplatin-induced AKI. Recent studies have found that cisplatin alters renal cell
metabolism, contributing to injury and the common occurrence of CKD
development.
Several studies have found that cisplatin treatment leads to renal tubular cell
depletion of amino acids, caused by both elevated levels of aminoaciduria and
decreased tubular reabsorption of amino acids (86-89). Interestingly, branchedchain amino acids such as leucine, isoleucine, and valine were found to be
elevated in urine and decreased in serum (86, 90). Many have discussed if this
phenomenon could be used as either a biomarker for prediction of susceptibility
to nephrotoxicity or enable earlier detection of kidney injury following cisplatin
treatment (86). Moreover, cisplatin influences lipid metabolism through the
reduction of fatty acid oxidation resulting in accumulation of fatty acids in kidney
tissue (86, 89, 91). Likewise, diacylglycerols, triacylglycerols, ceramides, and
neutral lipids accumulate in kidney tissue (86, 87, 92). Cisplatin also impacts
glycolysis through the reduction of glycolytic enzymes, thus, glucose will
accumulate while metabolites of glycolysis decrease (86, 93). In addition to
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glycolysis, cisplatin also decreases intermediates of the pentose phosphate
pathway and the citric acid cycle (86, 94).
These observations bring into question if susceptible patients could have an
altered renal cell metabolism, consequently, predisposing these patients to
nephrotoxic injury from cisplatin. This hypothesis will be further discussed and
investigated later in this dissertation.

8. Mitochondrial dysfunction and susceptibility to cisplatin toxicity
It has been well established that cisplatin nephrotoxicity induces cell death via
both apoptosis and necrosis. However, the mechanisms by which cisplatin
induces these pathways remains unclear. Recent evidence reveals that ROS and
mitochondrial function play an important role in cisplatin’s mechanism of injury
(95). Mitochondria continuously produce ROS, such as superoxide, and
scavenge these ROS using antioxidant enzymes (superoxide dismutase,
glutathione peroxidase, catalase, and glutathione S-transferase) (96). Moreover,
cisplatin has been found to also accumulate in the mitochondria of renal epithelial
cells (97, 98). Several studies show that cisplatin induces ROS in renal epithelial
cells by decreasing the activity of antioxidant enzymes along with the depletion of
intracellular glutathione (GSH) concentrations (99-102). Furthermore, there are
additional studies that demonstrate that pre-treatment with antioxidants such as
GSH is beneficial in reducing cisplatin’s nephrotoxicity (103, 104).
However, other studies suggest that at least in cultured proximal tubule cells,
the primary cause of cell death post cisplatin treatment may be far more related
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to mitochondrial dysfunction than ROS formation (100, 105). Several of these
studies show that cisplatin induces mitochondrial dysfunction, primarily through
targeting enzymatic complexes that comprise the electron transport chain (ETC)
(100, 105). Once the ETC is compromised, proximal tubule cells show a
significant reduction in ATP, with a rapid metabolic collapse and necrotic cell
death (28, 106). Additionally, slighter amounts of ATP depletion in tubule cells
have been associated with lower doses of cisplatin (106, 107). Lower amounts of
ATP depletion lead to apoptosis through the release of mitochondrial cytochrome
c in tubule cells (106, 107). Similarly, to other aspects of cisplatin injury, the
mechanism by which cisplatin causes cytochrome c release remains
controversial. Two proposed mechanisms include induction of mitochondrial
permeability transition (107) and increases in mitochondrial transmembrane
potential (106). Likewise, the mechanism behind cisplatin’s ability to inhibit the
enzymatic complexes of the ETC are also unclear.
If ATP depletion and mitochondrial dysfunction play a central role in cisplatininduced cell death, then how does one explain the supporting evidence for ROS
formation triggering cell death following cisplatin exposure? One possibility is that
these two processes co-exist, and are not mutually exclusive in regards to
cisplatin-induced cell death (8). It is possible that while the amount of ATP
depletion may induce the primary cell injury and influence the cell death pathway,
it may also accelerate ROS formation from the damaged cells (8), thus,
contributing to an amplification loop leading to ROS mediated cell death (8).
Especially since reduction in ROS through the pre-treatment of antioxidants can
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alleviate nephrotoxicity (103, 104), this may limit this amplification loop and
reduce the accompanying inflammatory response (100).
Collectively, it is evident that both ROS production and mitochondrial
dysfunction remain conceivable mechanisms of cisplatin-induced renal cell
death. With this knowledge it brings into question if renal cells containing higher
amounts of ROS and/or mitochondrial dysfunction could prime these cells for a
‘second hit’ with cisplatin, therefore, sensitizing these cells to cisplatin
nephrotoxicity and possibly clarifying why some patients are more susceptible to
cisplatin-induced AKI. This proposed mechanism will be further investigated
throughout this dissertation.

9. Statement of goals
It is well established that cisplatin’s limiting factor is its nephrotoxicity, but the
mechanism of toxicity remains uncertain. Moreover, there are no methods to
predict which patients are susceptible to injury and there are no targeted
therapies to halt or reverse the development of AKI. Development of such
methods or therapies requires a better understanding of mechanisms of disease
progression as well as identification of novel drug targets. Therefore, one goal of
this dissertation is to shed new insight into mechanisms of susceptibility to
cisplatin-induced AKI. Additionally, it has been established that loss of the
NHERF1 protein in mice predisposes these animals to cisplatin nephrotoxicity
(35). Another goal of this dissertation is to elucidate mechanisms by which
NHERF1 loss affects the kidneys. Taken together, the goal of this dissertation is
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to both understand the role NHERF1 plays in cisplatin nephrotoxicity and to
speculate on its potential use as a biomarker and/or therapeutic target.

B. Aims and proposals

1. Characterization of metabolic differences in kidneys of WT and
NHERF1 KO mice
As discussed in earlier sections, cisplatin significantly alters areas of
metabolic function and cellular homeostasis. In addition, mitochondria are
essential for maintaining this homeostasis. Mitochondria are responsible for ATP
production and in regulating the cell death pathways of apoptosis and necrosis.
Our laboratory has also established that loss of the NHERF1 scaffolding protein
predisposes mice to cisplatin-induced AKI (35). Understanding the mechanism of
susceptibility of these animals may be beneficial in understanding disease
development of cisplatin-induced AKI along with potentially providing future
therapeutic targets. Preliminary data from our laboratory suggested that NHERF1
KO mice may have an altered metabolic function. This was in part supported by
proteomic analysis of the brush border membrane (BBM) of WT and NHERF1
KO mouse kidneys. This analysis showed notable decreases in mitochondrial
proteins in the NHERF1 KO BBM. Furthermore, Seahorse XF24 analysis of
isolated proximal tubule cells from WT and NHERF1 KO mouse kidneys
exhibited a decrease in oxygen consumption rate (OCR). These results suggest
that metabolic changes may play an important role in the sensitization of the
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NHERF1 KO kidney to insult. This is supported by the following: [1] NHERF1
deficient cells do not grow as rapidly as normal proximal tubule cells, suggesting
that these cells are stressed. [2] NHERF1 KO mice treated with cisplatin display
a significant increase in BUN levels that are consistent with a more severe renal
injury when compared with treated WT mice (35). [3] Semi-quantitative scoring in
a blinded study showed cisplatin treated NHERF1 KO kidneys have a higher
level of severity in injury based on number of tubular casts, degree of ATN, and
BBM sloughing (35). [4] Levels of apoptosis are similar between cisplatin treated
WT and NHERF1 KO kidneys, indicating that damaged NHERF1 KO kidneys
may have a higher level of ATP depletion resulting in higher levels of necrotic cell
death (35). [5] Anaerobic glycolysis, a hallmark of AKI, is known to increase in
rodent models treated with cisplatin (108) and in models of ischemic reperfusion
(109) concomitant with a decrease in aerobic metabolism. The goal of this aim
was to define any metabolic differences between kidneys of WT and NHERF1
KO mice. This study evaluated gluconeogenic, glycolytic, and pentose phosphate
enzyme activity along with measuring ATP content of WT and NHERF1 KO
mouse kidneys under basal and cisplatin treated conditions.

2. Identification of changes in mitochondrial function in NHERF1 KO
mice kidneys
Cisplatin is known to accumulate in renal cell mitochondria and can damage
mitochondrial enzymatic complexes. Additionally, mitochondrial dysfunction is
one potential mechanism of cisplatin-induced renal cell death. It was
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hypothesized that an underlying mitochondrial dysfunction in NHERF1 KO
kidneys may lead to sensitization of cisplatin nephrotoxicity. Furthermore, two
proposed potential causes of mitochondrial dysfunction were: [1] Decrease in
mitochondrial OCR also known as oxidative phosphorylation and/or alterations in
mitochondrial structure in NHERF1 KO kidneys. [2] Decrease in number of
mitochondria in NHERF1 KO kidneys. Therefore, electron microscopy (EM) was
utilized to analyze both the mitochondrial morphology, distribution, and number of
mitochondria in WT and NHERF1 KO kidneys. Additionally, mitochondria were
isolated from WT and NHERF1 KO kidneys to evaluate function using the
Seahorse XF24 Analyzer. This builds upon the work in Aim 1 of this dissertation,
further evaluating metabolic and mitochondrial homeostasis as a potential
mechanism of susceptibility to cisplatin nephrotoxicity in NHERF1 KO mice.

3. Identification of mechanisms for enhanced cisplatin injury in
NHERF1 KO mice
Recently, a study showed that cervical cancer cells that are NHERF1
deficient have cisplatin resistance (110). Our laboratory previously established
that NHERF1 KO mice have exacerbated cisplatin nephrotoxicity (35).
Collectively, these data suggest that loss of NHERF1 may alter cisplatin cellular
uptake and/or metabolism. Cisplatin metabolism begins with conjugation to GSH
and within renal proximal tubule cells results in a nephrotoxic metabolite,
cisplatin-thiol conjugate which is reactive and unstable and thus damages the
mitochondria (111). Previous studies in mice and rats found that inhibition of
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GGT and CCBL, involved in cisplatin metabolism, blocked the nephrotoxic effects
of cisplatin (26, 112, 113). In in vitro studies, different cisplatin GSH conjugates
led to more cell death to tubule cells than cisplatin alone (114). Aim 3 of this
dissertation tests the hypothesis of potential changes in renal handling of
cisplatin in NHERF1 KO mice. This was tested through the evaluation of lipid
peroxidation, levels of small molecular weight thiols that act as antioxidants (e.g.
GSH and Cysteine (Cys)), enzymatic activity of GGT, GGT and CCBL protein
levels via western blot, and localization of GGT. Additionally, multiple time points
(4 hours, 24 hours, and 72 hours) were evaluated based upon the established
pharmacokinetics of cisplatin (115, 116).

Overall aim of this dissertation.
The overall aim of this dissertation is to provide new insight into mechanisms
of susceptibility to cisplatin-induced AKI. To this end, the role of NHERF1 and
sensitivity to cisplatin is a novel hypothesis that has not previously been
investigated. Additionally, 3 potential mechanisms of susceptibility were
investigated in this dissertation. [1] metabolic changes in NHERF1 KO mice
kidneys (Aim 1) [2], mitochondrial function, morphology, and number in NHERF1
KO kidneys (Aim 2) [3], altered renal handling of cisplatin in NHERF1 KO kidneys
(Aim 3). Taken together, this work will shed new mechanistic insight into
cisplatin-induced AKI.
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CHAPTER II

EXPERIMENTAL PROCEDURES

A. Animals and treatments
Animal experiments were carried out by the Lederer laboratory. Mice were
housed in a pathogen-free barrier facility, accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care. All animals used in
these studies and procedures were in accordance with the guidelines established
by University of Louisville’s Institutional Animal Care and Use Committee
(IACUC).

1. Animal sacrifice, tissue collection, and storage
At the time of sacrifice, animals were anesthetized with ketamine/xylazine
(100/15 mg/kg, intraperitoneally (IP)). Blood was collected before sacrifice and
plasma was extracted by centrifugation (10,000xg for 10 minutes). Plasma was
stored at -80 ⁰C until further analysis. Kidneys were removed and decapsulated.
Portions of the kidney were snap-frozen in liquid nitrogen or immediately had the
cortex separated from the rest of the kidney. The cortex was then either
homogenized, frozen-fixed in Tissue Tek OCT-Compound (Sakura Finetek,
Torrance, CA) or immersed in 3.7% formaldehyde in phosphate buffered saline
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(PBS) for 24 hours followed by 70% ethanol prior to paraffin embedding for
histology.

2. Acute model of cisplatin nephrotoxicity
Male (2-4 month old) WT C57BL/6J and C57BL6J NHERF1

(-/-)

KO mice (46)

were maintained on a 12:12 hour light-dark cycle and were provided water and
food ad libitum. Mice received a single IP injection of 20 mg/kg cisplatin
(University of Louisville hospital pharmacy) or vehicle (saline). Vehicle treated
and cisplatin treated mice were euthanized after 4, 24, and 72 hours. All studies
were performed at the same time each day.

B. Enzyme kinetics
1. Tissue preparation
Kidney cortex was homogenized in 0.1 M Tris-HCl, pH 7.4 on ice. Tissue
homogenates were then sonicated on ice for 10 seconds/sample. The samples
were then centrifuged for 15 minutes at 2,500xg at 4°C.

2. Fructose-1,6-Bisphosphatase activity assay
Solutions of 0.1 M Tris-HCl, pH 8.6; 0.1 MgCl2; 0.1 M Cysteine HCl; 50 mM
fructose-1,6-bisphosphatase (FBPase) were prepared. All components were
added to tissue samples, except FBPase. Blanks were then prepared for the
assay (solution blank and sample blank in solution). Each reaction was run in a
96 well plate with the FBPase added last to all samples and incubated for 60
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minutes at 37°C. 10% trichloroacetic acid (TCA) was used to stop the reaction
after the allotted time. Once a precipitate formed the plate was centrifuged at
10,000xg for 10 minutes to lower the precipitate to the bottom of the well. 5g of
FeSO4 was dissolved in 10 mL of 10% ammonium molybdate for working
standards. FeSO4 working standards were prepared (0, 10, 25, 50, 100,150, 200,
250 nM) and added to a new 96 well plate. For each sample 50 μL of the first
reaction was then added to the new plate. Then 40 μL of the FeSO4 solution was
added last to each standard and sample well and incubated at room temperature
for 10 minutes. The plate was read at 10 minutes at 820 nm. (WT vehicle n=3),
(NHERF1 KO vehicle n=4), (WT cisplatin n=3), (NHERF1 KO cisplatin=5).

3. Glucose-6-Phosphatase activity assay
0.1 M Tris-HCl, pH 7.4; 10% TCA; 50 mM glucose-6-phosphatase (G6Pase);
0.1M MgCl2 were prepared. Additionally, a 3.2 mM KH2PO4 solution was
prepared and stored at 4°C. All working standards were prepared fresh using the
3.2 mM KH2PO4 stock solution and diluted to 590 μM. Blanks were then prepared
for the assay (solution blank and sample blank in solution). Each reaction was
run in a 96 well plate with the G6Pase added last to all samples. The plate was
then incubated for 60 minutes at 37°C. 10% TCA was used to stop the reaction
after the allotted time. Once a precipitate formed the plate was centrifuged at
10,000xg for 10 minutes to lower the precipitate to the bottom of the well. 5g of
FeSO4 was dissolved in 10 mL of 10% ammonium molybdate for working
standards. FeSO4 working standards were prepared (0, 10, 25, 50, 100,150, 200,

33

250 nM) and added to a new 96 well plate. Then 50 μL of the FeSO4 solution was
added last to each standard and sample well and incubated at room temperature
for 10 minutes. The plate was read at 10 minutes at 820 nm. (WT vehicle n=3),
(NHERF1 KO vehicle n=4), (WT cisplatin n=3), (NHERF1 KO cisplatin=5).

4. Lactate Dehydrogenase activity assay
0.1 M Tris-HCl, pH 7.4; 0.5 mM sodium pyruvate; 0.1M MgCl2 were prepared.
Additionally, 0.5 mM NADH was made fresh in a 1mM sodium bicarbonate, pH
9.0 solution the day of the reaction. Blanks were then prepared for the assay
(solution blank and sample blank in solution). Each reaction was run in a 96 well
plate with the NADH added last to all samples. The plate was read immediately
after adding the NADH at 340 nm for 3-10 minutes. (WT vehicle n=3), (NHERF1
KO vehicle n=4), (WT cisplatin n=3), (NHERF1 KO cisplatin=5).

5. Malate Dehydrogenase activity assay
0.1 M Tris-HCl, pH 7.4; 0.5 mM oxaloacetate; 0.1M MgCl2 were prepared.
Additionally, 0.5 mM NADH was made fresh in a 1mM sodium bicarbonate, pH
9.0 solution the day of the reaction. Blanks were then prepared for the assay
(solution blank and sample blank in solution). Each reaction was run in a 96 well
plate with the NADH added last to all samples. The plate was read immediately
after adding the NADH at 340 nm for 3-10 minutes. (WT vehicle n=3), (NHERF1
KO vehicle n=4), (WT cisplatin n=3), (NHERF1 KO cisplatin=5).
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6. Malic Enzyme activity assay
0.1 M Tris-HCl, pH 7.4; 0.5 mM L-malic acid; 0.1M MgCl2 were prepared.
Additionally, 2mg/mL of NADP was made fresh in a 100 mM imidazole solution
the day of the reaction. Blanks were then prepared for the assay (solution blank
and sample blank in solution). Each reaction was run in a 96 well plate with the
NADP added last to all samples. The plate was read immediately after adding the
NADP at 340 nm for 3-10 minutes. (WT vehicle n=3), (NHERF1 KO vehicle n=4),
(WT cisplatin n=3), (NHERF1 KO cisplatin=5).

7. Glucose-6-Phosphate Dehydrogenase activity assay
0.1 M Tris-HCl, pH 7.4; 0.5 mM glucose-6-phosphate; 0.1M MgCl2 were
prepared. Additionally, 2mg/mL of NADP was made fresh in a 100 mM imidazole
solution the day of the reaction. Blanks were then prepared for the assay
(solution blank and sample blank in solution). Each reaction was run in a 96 well
plate with the NADP added last to all samples. The plate was read immediately
after adding the NADP at 340 nm for 3-10 minutes. (WT vehicle n=3), (NHERF1
KO vehicle n=4), (WT cisplatin n=3), (NHERF1 KO cisplatin=5).

8. γ-Glutamyl Transferase activity assay
The activity assay was performed using the GGT colorimetric assay kit
(Sigma Aldrich; St. Louis, Missouri) per the manufacturer’s instructions. Tissue
samples were prepared using approximately 10 mg of kidney cortex in 200 μL of
ice-cold GGT assay buffer. The samples were then centrifuged at 13,000xg for
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10 minutes to remove insoluble material. The supernatant was kept and further
diluted to 1:100 using GGT assay buffer and stored at -80°C until further use. 4
hours: (WT vehicle: n=6), (NHERF1 KO vehicle: n=6), (WT cisplatin: n=6), and
(NHERF1 KO cisplatin: n=6) and 24 hours: (WT vehicle: n=5), (NHERF1 KO
vehicle: n=5), (WT cisplatin: n=7), and (NHERF1 KO cisplatin: n=8).

C. Liquid Chromatography-Mass Spectrometry (LC-MS)
1. LC-MS of kidney cortex for ATP quantification
10 mg of kidney cortex was snap-frozen and stored in -80 °C until LC-MS
procedure. The tissue was maintained in liquid nitrogen during preparation for
LC-MS. Tubes and beads were pre-cooled in liquid nitrogen and 2.5% kidney
cortex homogenate was made using an extraction solution (70% acetonitrile and
30% H2O). Tissue was homogenized using a bead beater at 5 m/s for 15
seconds. The homogenized tissue was then transferred to another tube for
centrifugation at 16,000xg for 10 min at 4°C. The supernatant was saved for
subsequent LC-MS analysis. To quantitate the ATP present in mouse kidney
cortex tissue a standard curve was prepared using 1mM ATP diluted serially with
the extraction buffer containing 20µM 13C10ATP. Each concentration point was
diluted 50X with 60% ACN and 40% 15mM Ammonium Acetate. 5µL was
injected onto a SeQuant ZIC-cHILIC 100X2.1mm metal free HPLC column.
Separation was performed by pumping 60% ACN and 40% 15mM Ammonium
Acetate through the column with a flow rate of 0.5mL/min with no change in
composition using a Waters Acquity UPLC. The ATP was eluted from the column
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and flowed into a Waters Quattro Premier XE mass spectrometer and
subsequently quantitated using optimized MRMs. A calibration curve was
constructed using ATP concentration on the x-axis and response of ATP over
13C ATP
10

on the y axis. Mouse kidney extracts were also diluted with 50X 60%

ACN and 40% 15mM Ammonium Acetate, 5µL was injected and the
concentration in kidney tissue was interpolated using the calibration curve
previously made for (WT n=5) and (NHERF1 KO n=5).

D. Electron Microscopy
1. Perfusion fixation of total kidney in situ for electron microscopy
The abdominal cavity of the mouse was opened along the linea alba and
intestines moved aside to expose kidneys. A suture was loosely put around the
right kidney for removal without glutaraldehyde exposure. The right kidney was
then used for kidney cortex homogenates. Next, the chest cavity was opened to
expose the heart and the vena cava was cut while the right kidney was tied off
and removed. The left mouse kidney was perfused with 3% glutaraldehyde
solution at a rate of 6 mL/min for approximately 1-3 minutes. Perfusion was
stopped once kidneys had a change in color and consistency. The kidney was
removed and placed in a petri dish of 3% glutaraldehyde where three to four 0.2
cm x 0.4 cm slices were cut and then stored in 3-4 mL of 3% glutaraldehyde at
4°C. At this point the tissue was sent to Norton Children’s Hospital Pathology
Department for a blinded EM analysis of kidney tubule mitochondria. Images
were taken by a renal pathologist at the Pathology Department. Sections with the
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highest concentration of mitochondria were randomly picked in a 4x field to be
used to calculate mitochondria number and mitochondria area by Image J (WT
n=6) and (NHERF1 KO n=5).

E. Seahorse XF24 mitochondrial respiration analysis
Mice for this study had food taken away 6 hours before sacrifice.
Mitochondrial oxidative capacity was measured in isolated kidney mitochondria
using a Seahorse Bioscience XF24 extracellular flux analyzer (Billerica, MA,
USA). For measurements in isolated mitochondria, tissue from the kidney cortex
of both kidneys (approximately 50 mg) was isolated and homogenized in 1 ml of
isolation buffer (220 mM mannitol, 70 mM sucrose, 5 mM 3-(Nmorpholino)propanesulfonic acid (MOPS), 1 mM ethylene glycol tetraacetic acid
(EGTA), 0.3% fatty acid-free bovine serum albumin (BSA), pH 7.2). The
homogenate was centrifuged at 500 x g for five minutes at 4°C. The supernatant
containing mitochondria was centrifuged at 10,000 x g for five minutes. Following
two wash centrifugation steps in BSA-free isolation buffer, the mitochondria were
suspended in respiration buffer (120 mM KCl, 25 mM sucrose, 10 mM 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1 mM MgCl2, 5 mM
KH2PO4, pH to 7.2). Protein in the mitochondrial suspension was estimated by
bicinchoninic acid method (Sigma) using BSA as a standard. 10 μg of
mitochondrial protein was sedimented in XF culture plates. Succinate (10 mM),
rotenone (1 μM), and ADP (1 mM) were injected to assess state 3 respiratory
activity (phosphorylating respiration). The OCR of mitochondria after exposure to
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oligomycin (1 μg/ml) was used to estimate state 4 activity (non-phosphorylating
respiration). Finally, Antimycin A (20 μM) was stop all respiration. Data are
expressed as pmol O2/min/μg protein (WT n=6, NHERF1 KO n=6).

F. Histology and immunohistochemistry
1. Histology
Paraffin embedded fixed whole kidney tissue were cut in 5 μm thick either
transversely or longitudinally from cisplatin treated and vehicle treated WT and
NHERF1 KO animals. These sections were stained with hematoxylin and eosin
(H&E) as well as periodic acid-schiff (PAS) to evaluate number of casts, degree
of BBM sloughing, and ATN. These sections were sent to a pathologist for
analysis. Images were taken at 20x and 40x (WT vehicle n=5), (NHERF1 KO
vehicle n=5), (WT cisplatin n=7), and (NHERF1 KO cisplatin n=8).

2. Immunohistochemistry (IHC)
IHC was carried out on paraffin embedded fixed whole kidney tissue cut in 5
μm thick sections either transversely or longitudinally from cisplatin treated and
vehicle treated WT and NHERF1 KO animals. A primary antibody against GGT
(1:50) (ABclonal; Woburn, MA; A1776) and 4-Hydroxynonenal (4-HNE) (1:100)
(Abcam; Cambridge, UK; ab46545) were utilized for staining to evaluate any
changes in proximal tubule localization or loss after cisplatin treatment. Images
were taken at 10x, 20x and 40x (WT vehicle: n=5), (NHERF1 KO vehicle: n=5),
(WT cisplatin: n=10), and (NHERF1 KO: n=9).
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G. Clinical Chemistry
1. Neutrophil gelatinase-associated lipocalin (NGAL)
NGAL was determined using an enzyme linked immunosorbent assay
(ELISA) kit (R&D Systems; Minneapolis, MN; DY1857) on mouse urine as
directed by the manufacturer (WT vehicle n=5), (NHERF1 KO vehicle n=5), (WT
cisplatin n=7), and (NHERF1 KO cisplatin n=8).

H. Thiobarbituric acid reactive substances (TBARS)
Lipid peroxidation was determined using a TBARS assay kit (Cayman
Chemicals; Ann Arbor, MI; 10009055) on mouse kidney cortex tissue as directed
by the manufacturer (WT vehicle n=5), (KO vehicle n=5), (WT cisplatin n=8), and
(NHERF1 KO cisplatin n=9).

I. High-performance Liquid Chromatography (HPLC)
1. Collection of Mouse Blood and Tissue for GSH, GSSG, Cys, and Cyss
Blood samples were collected from mice and added to a tube with 0.5 M
borate buffer stock solution and 165 uM γ-glutamylglutamate as the internal
standard as described in (117) within 1-2 minutes after the blood was drawn.
Plasma was extracted via centrifugation (3,000xg for 2 minutes) and 50 uL of
supernatant was transferred to a new tube with preservation solution (10%
perchloric acid, 0.2 M boric acid, and 10 uM γ-glutamylglutamate). Tubes were
then stored at -80°C. 10 mg of kidney cortex tissue was removed from the kidney
and added to preservation solution (5% perchloric acid, 0.2 M boric acid, and 10
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uM γ-glutamylglutamate) and homogenized. Kidney cortex homogenates were
then stored at -80° until further use. Plasma: (WT vehicle: n=5), (NHERF1 KO
vehicle: n=5), (WT cisplatin: n=7), and (NHERF1 KO cisplatin: n=9).

2. HPLC Analysis of kidney cortex and plasma for GSH, GSSG, Cys, and
CySS
Tissue and plasma Cys, CySS, GSH and GSSG were assayed by HPLC as
S-carboxymethyl, N-dansyl derivatives using γ-glutamylglutamate as an internal
standard as previously described (117, 118). The HPLC system consisted of an
aminopropyl column, 2 Waters 515 HPLC Pumps to deliver a gradient of acetate
and methanol, a Waters 717 plus Autosampler with refrigeration unit, and a
Waters 2475 Multi λ Fluorescence Detector. Integration of peak areas and
comparison to internal standard was performed by Waters Empower 3 software.
Kidney: (WT vehicle: n=5), (NHERF1 KO vehicle: n=5), (WT cisplatin: n=8), and
(NHERF1 KO cisplatin: n=9).

J. Immunoblots
1. Western blot
Kidney cortex homogenates were made as previously described (119).
Protein concentration was measured by bicinchoninic acid (BCA) method
(Sigma) using BSA as a standard. Kidney homogenates were separated by 10%
SDS-PAGE and transferred to nitrocellulose membranes. The membranes were
incubated with 5% (wt/vol) dried milk in Tris-buffered saline with 0.5% Tween 20
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(TTBS) for 30 minutes to decrease nonspecific antibody binding. Membranes
were incubated overnight at 4°C with primary antibodies against GGT (ABclonal;
A1776) and CCBL1 (ABclonal; A6542), diluted (1:1000) in 5% milk. Membranes
were washed with TTBS and incubated for 2 hours with horseradish peroxidaseconjugated secondary antibodies diluted in TTBS and 5% milk.
Chemiluminescence (ThermoScientific) was utilized to detect bands and
visualization via GeneSys software with a Pixi imaging system (Syngene).
Densitometric analysis was performed via Image J. For densitometric analysis,
specific protein expression was normalized to densitometry values for
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Cell Signaling; Beverly,
MA) or β-actin (Cell Signaling) in each lane (WT vehicle n=3), (NHERF1 KO
vehicle n=3), (WT cisplatin n=4), and (NHERF1 KO cisplatin n=4).

L. Statistical analysis
1. Statistical analysis of ATP, mitochondrial number, and respiration
data
Student’s t-test was used to evaluate LC-MS data measuring ATP content
between WT and NHERF1 KO kidneys. Additionally, student’s t-test was used to
compare mitochondrial number and mitochondrial respiration via Seahorse XF24
between WT and NHERF1 KO kidney mitochondria. P-values of <0.05 were
considered statistically significant and data were shown as mean ± standard
error means (SEM).

42

2. Statistical analysis of enzyme kinetics, western blots, HPLC, NGAL,
and TBARS
Two-way analysis of variance (ANOVA) was used to evaluate changes in
enzyme kinetics between vehicle and cisplatin treated mouse kidneys. Likewise,
two-way ANOVA was utilized to evaluate protein expression changes in GGT
and CCBL in treated kidney cortex by western blot; reduction/oxidation state of
GSH and Cys in plasma and treated kidneys; lipid peroxidation by TBARS in
treated kidneys; and urine NGAL from treated mice. P-values of <0.05 were
considered statistically significant and data were shown as mean ± SEM.
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CHAPTER III

NHERF1 LOSS RESULTS IN ALTERED PENTOSE PHOSPHATE ENZYMES IN
MICE

A. Introduction
Although cisplatin is a widely used chemotherapeutic that treats a variety of
solid malignant tumors (e.g. ovarian testicular, head and neck, and lung cancer),
its mechanism of action is still not completely understood (8). Likewise, the
mechanism of cisplatin’s nephrotoxicity remains perplexing and is surrounded by
much controversy. Moreover, 20-30% of patients on cisplatin will develop
cisplatin-induced AKI with a single dose (8). Currently, there are no methods of
prevention for cisplatin-induced AKI or therapeutics to treat the development of
AKI. Therefore, understanding patient susceptibility to cisplatin is a needed area
of research.
Identifying new potential biomarkers and/or therapeutic targets are a
promising area of research. To meet this need, a new area of research has been
proposed to involve the scaffolding protein NHERF1 and susceptibility to
cisplatin-induced AKI (35). NHERF1 is a known monomeric intrinsic membrane
protein that belongs to the NHERF family of PDZ-scaffold proteins (31). NHERF1
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is found in all epithelial cells and acts as a scaffold for multi-protein signaling
complexes. In proximal tubule cells of the kidney NHERF1 is anchored to the
cytoskeleton in the subapical plasma membrane where it acts as a key
scaffolding protein of transport proteins and has critical roles in defining the renal
proximal tubule BBM composition and in regulating ion transport (31).
Furthermore, there is increasing evidence that NHERF1 has a much broader role
than as a scaffolding protein. In fact, NHERF1 expression and/or localization has
been associated with tumorigenesis (33, 34). Several studies have documented
when NHERF1 is localized at the apical membrane it acts as a tumor suppressor,
and when its expression is lost or its localization is in the cytoplasm or nucleus it
exhibits pro-oncogenic properties (33, 34). Additionally, NHERF1 has received
increased interest in its involvement in a variety of functions including: cell
structure and trafficking (38, 40), inflammatory responses (82), and tissue injury
(35-37). One such study found that NHERF1 KO mice had attenuated cholestatic
liver injury by bile duct ligation (36). NHERF1 loss has been reported in
exacerbation of cisplatin-induced AKI in mice (35). Furthermore, aging rats (22
months) exhibit a decrease in NHERF1 expression (84) associated with the
development of renal fibrosis.
Taken together, NHERF1 expression may also be lost in aging humans,
predisposing these patients to cisplatin nephrotoxicity. One question addressed
in this dissertation is whether NHERF1 loss may alter metabolic pathways
resulting in increased sensitivity to cisplatin. Cisplatin itself is known to modify
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renal metabolic pathways such as glycolysis, gluconeogenesis, and lipid
metabolism in response to cellular injury and death (86, 87, 92, 93).

B. Experimental Procedures
1. Animals and treatments
Male (2-4 month) WT and NHERF1 KO mice were treated with cisplatin (20
mg/kg IP) for 72 hours as described in Chapter II.

2. LC-MS of kidney cortex for ATP quantification
Snap-frozen kidneys were prepared for LC-MS analysis as described in
Chapter II.

3. Enzyme kinetics
Kidney cortex tissue was homogenized and prepared for enzyme kinetic
assays as described in Chapter II. Enzyme kinetic assays were run for FBPase,
G6Pase, lactate dehydrogenase (LDH), malate dehydrogenase (MDH), malic
enzyme, and glucose-6-phosphate dehydrogenase (G6PD) as described in
Chapter II.

4. Data analysis
Enzyme kinetic data were analyzed as described in Chapter II.

5. Statistical analysis
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Enzyme kinetic data were analyzed by two-way ANOVA as described in
Chapter II.

C. Results
1. Cisplatin treatment significantly decreases fructose-1,6bisphosphatase enzyme activity in both WT and NHERF1 KO mice.
Previous studies investigated the effect of cisplatin on gluconeogenesis (86,
93, 120). However, the effect of NHERF1 protein loss on gluconeogenesis before
and after cisplatin treatment has not been investigated. The first objective of this
dissertation was to measure the enzyme activity of FBPase before and after
cisplatin treatment in WT and NHERF1 KO mice. FBPase is a critical regulatory
enzyme in gluconeogenesis that catalyzes the hydrolysis of fructose-1,6bisphosphate to fructose-6-phosphate and inorganic phosphate (121). In order to
determine if NHERF1 loss affected gluconeogenic enzyme activity alone or with
cisplatin treatment, male 2-4 month old mice were treated with vehicle or cisplatin
to induce AKI and then sacrificed after 72 hours. Kidney cortex tissue from these
mice were used for the FBPase enzyme kinetic assay as described in Chapter II.
There were no significant differences between vehicle [(WT: 41.5 nmole/mg
protein/min ± 6.5) (KO: 38.7 nmole/mg protein/min ± 4.1)] or cisplatin [(WT: 20.6
nmole/mg protein/min ± 0.4) (KO: 19.7 nmole/mg protein/min ± 1.2)] treated WT
and NHERF KO kidneys (Figure 3.1). However, cisplatin did decrease FBPase
activity in both WT and NHERF1 KO kidneys (P = 0.0001) (Figure 3.1).
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Figure 3.1

Figure 3.1: Effect of cisplatin treatment on fructose-1,6-bisphosphatase enzyme
activity in WT and NHERF1 KO mouse kidneys.
2-4 month old male C57BL/6J WT and NHERF1 KO mice were given cisplatin
(20 mg/kg dose IP) or vehicle (saline) and sacrificed after 72 hours as described
in Chapter II. FBPase enzyme activity was determined from kidney cortex tissue
of these mice. Data are means ± SEM (WT vehicle n=3), (KO vehicle n=4), (WT
cisplatin n=3), and (KO cisplatin n=5). ***P = 0.001 cisplatin treated WT and
NHERF1 KO mice compared to vehicle saline controls.
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2. Cisplatin treatment significantly decreases glucose-6-phosphatase
enzyme activity in both WT and NHERF1 KO mice.
G6Pase is the final step in gluconeogenesis. It hydrolyzes glucose-6phosphate to free glucose and a phosphate group (122). This enzyme was also
investigated to evaluate the effect NHERF1 loss may have on gluconeogenesis
alone or with cisplatin treatment. Kidney cortex tissue from these mice were used
for the G6Pase enzyme kinetic assay as described in Chapter II. Similarly to
FBPase, G6Pase activity remained comparable in WT and NHERF1 KO kidneys
regardless of treatment [(WT vehicle: 92.3 nmole/mg protein/min ± 5.0), (KO
vehicle: 103.0 nmole/mg protein/min ± 11.3), (WT cisplatin: 38.0 nmole/mg
protein/min ± 5.1), and (KO cisplatin: 26.4 nmole/mg protein/min ± 3.8)], while
cisplatin led to a significant decrease in enzyme activity in both genotypes (P
<0.0001) (Figure 3.2).

3. NHERF1 loss or cisplatin treatment does not significantly affect
lactate dehydrogenase enzyme activity in mice.
Lactate dehydrogenase (LDH) catalyzes the interconversion of lactate and
pyruvate, concomitantly with the interconversion of NADH and NAD+ (123) .
When oxygen is absent LDH converts pyruvate, the final product of glycolysis, to
lactate (123). Kidney cortex tissue from WT and NHERF1 KO vehicle and
cisplatin treated mice were used to evaluate enzyme activity of LDH as described
in Chapter II. NHERF1 loss (P = 0.65) or cisplatin treatment (P = 0.71) did not
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Figure 3.2

Figure 3.2: Effect of cisplatin treatment on glucose-6-phosphatase enzyme
activity in WT and NHERF1 KO mouse kidneys.
2-4 month old male C57BL/6J WT and NHERF1 KO mice were given cisplatin
(20 mg/kg dose IP) or vehicle (saline) and sacrificed after 72 hours as described
in Chapter II. G6Pase enzyme activity was determined from kidney cortex tissue
of these mice. Data are means ± SEM (WT vehicle n=3), (KO vehicle n=4), (WT
cisplatin n=3), and (KO cisplatin n=5). ***P < 0.001 cisplatin treated WT and
NHERF1 KO mice compared to vehicle saline controls.
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significantly affect lactate dehydrogenase activity in these mouse kidneys [(WT
vehicle: 0.06 nmole/mg protein/min ± 0.02), (KO vehicle: 0.1 nmole/mg
protein/min ± 0.05), (WT cisplatin: 0.1 nmole/mg protein/min ± 0.8), and (KO
cisplatin: 0.02 nmole/mg protein/min ± 0.006)] (Figure 3.3).

4. Cisplatin treatment significantly decreases malate dehydrogenase
enzyme activity in both WT and NHERF1 KO mice.
Malate dehydrogenase (MDH) is an enzyme involved in many metabolic
pathways including the citric acid cycle. MDH reversibly catalyzes the oxidation
of malate to oxaloacetate with the reduction of NAD+ to NADH (124). The effect
of NHERF1 loss and/or cisplatin treatment on MDH activity was analyzed. In a
similar way to LDH, NHERF1 loss or cisplatin treatment did not significantly affect
MDH activity in these mouse kidneys [(WT vehicle: 0.9 nmole/mg protein/min ±
0.06), (KO vehicle: 0.7 nmole/mg protein/min ± 0.02), (WT cisplatin: 0.8
nmole/mg protein/min ± 0.02), and (KO cisplatin: 0.81 nmole/mg protein/min ±
0.06)] (Figure 3.4).

5. NHERF1 loss affects malic enzyme activity before and after cisplatin
treatment.
Malic enzyme (ME) catalyzes the conversion of malic acid to pyruvate and
produces NADPH (125). ME serves as an additional source of NADPH for
lipogenesis. In order to understand the affect that NHERF1 loss and/or cisplatin
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Figure 3.3

Figure 3.3: Lactate Dehydrogenase enzyme activity in WT and NHERF1 KO
mouse kidneys.
2-4 month old male C57BL/6J WT and NHERF1 KO mice were given cisplatin
(20 mg/kg dose IP) or vehicle (saline) and sacrificed after 72 hours as described
in Chapter II. LDH enzyme activity was determined from kidney cortex tissue of
these mice. Data are means ± SEM (WT vehicle n=3), (KO vehicle n=4), (WT
cisplatin n=3), and (NHERF1 KO cisplatin n=5). No significant differences were
recorded.
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Figure 3.4

Figure 3.4: Malate Dehydrogenase enzyme activity in WT and NHERF1 KO
mouse kidneys.
2-4 month old male C57BL/6J WT and NHERF1 KO mice were given cisplatin
(20 mg/kg dose IP) or vehicle (saline) and sacrificed after 72 hours as described
in Chapter II. MDH enzyme activity was determined from kidney cortex tissue of
these mice. Data are means ± SEM (WT vehicle n=3), (KO vehicle n=4), (WT
cisplatin n=3), (NHERF1 KO cisplatin n=5). No significant differences were
reported.
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treatment may have on ME activity, kidney cortex tissue from vehicle or cisplatin
treated WT and NHERF1 KO were evaluated as described in Chapter II.
Interestingly, there was a significant genotype effect on ME activity resulting in an
increase in activity in NHERF1 KO kidneys (P = 0.0065) (Figure 3.5).
Additionally, a significant interaction affect was also noted between WT and
NHERF1 KO kidneys after cisplatin treatment (P = 0.0005) [(WT vehicle: 0.07
nmole/mg protein/min ± 0.012), (KO vehicle: 0.21 nmole/mg protein/min ± 0.01),
(WT cisplatin: 0.15 nmole/mg protein/min ± 0.012), and (KO cisplatin: 0.13
nmole/mg protein/min ± 0.02)] (Figure 3.5).

6. NHERF1 loss affects glucose-6-phosphate dehydrogenase enzyme
activity before and after cisplatin treatment.
Cisplatin-induced AKI is known to decrease intermediates of the pentose
phosphate pathway (86, 94) in mice. Glucose-6-phosphate dehydrogenase
(G6PD) is a cytosolic enzyme that participates in the pentose phosphate
pathway, resulting in NADPH production (126). This is accomplished when G6PD
reduces NADP+ to NADPH while oxidizing glucose-6-phosphate (126). G6PD
enzyme activity was analyzed in vehicle and cisplatin treated WT and NHERF1
KO kidney cortex to elucidate if NHERF1 loss and/or cisplatin treatment affected
the pentose phosphate pathway. Similarly to ME, there was a significant
genotype effect on G6PD activity resulting in an increase in activity in NHERF1
KO kidneys (P = 0.0033) (Figure 3.6). Additionally, a significant interaction affect
was also noted between WT and NHERF1 KO kidneys after cisplatin treatment
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Figure 3.5

Figure 3.5: Effect of NHERF1 loss and cisplatin treatment on malic enzyme
activity in WT and NHERF1 KO mouse kidneys.
2-4 month old male C57BL/6J WT and NHERF1 KO mice were given cisplatin
(20 mg/kg dose IP) or vehicle (saline) and sacrificed after 72 hours as described
in Chapter II. ME activity was determined from kidney cortex tissue of these
mice. Data are means ± SEM (WT vehicle n=3), (KO vehicle n=4), (WT cisplatin
n=3), and (KO cisplatin n=5). **P = 0.0065 vehicle treated NHERF1 KO mice
compared to WT vehicle controls; ***P = 0.0005 interaction of cisplatin treated
NHERF1 KO mice to cisplatin treated WT mice.
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Figure 3.6

Figure 3.6: Effect of NHERF1 loss and cisplatin treatment on glucose-6phosphate dehydrogenase enzyme activity in WT and NHERF1 KO mouse
kidneys.
2-4 month old male C57BL/6J WT and NHERF1 KO mice were given cisplatin
(20 mg/kg dose IP) or vehicle (saline) and sacrificed after 72 hours as described
in Chapter II. G6PD enzyme activity was determined from kidney cortex tissue of
these mice. Data are means ± SEM (WT vehicle n=3), (KO vehicle n=4), (WT
cisplatin n=3), and (KO cisplatin n=5). **P = 0.0065 vehicle treated NHERF1 KO
mice compared to WT vehicle controls; **P = 0.0005 interaction of cisplatin
treated NHERF1 KO mice to cisplatin treated WT mice.
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(P = 0.00029) [(WT vehicle: 0.13 nmole/mg protein/min ± 0.02), (KO vehicle: 0.3
nmole/mg protein/min ± 0.03), (WT cisplatin: 0.3 nmole/mg protein/min ± 0.007),
and (KO cisplatin: 0.3nmole/mg protein/min ± 0.02)] (Figure 3.6).

7. NHERF1 loss does not affect amount of ATP by LC-MS in mouse
kidneys.
ATP provides energy to drive many cellular processes and is consumed
during many metabolic processes (127). In eukaryotes ATP is produced by three
different metabolic pathways: [1] glycolysis, [2] the citric acid cycle or oxidative
phosphorylation, and [3] beta-oxidation (127). In order to determine if NHERF1
KO kidneys had differences in ATP content, kidneys were snap-frozen and
processed while cold for LC-MS as described in Chapter II. LC-MS analysis
revealed that there were no significant differences in ATP amount in WT (3.4
nmoles/mg tissue ± 0.5) and NHERF1 KO (3.1 nmoles/mg tissue ± 0.5) kidneys
(P = 0.67) (Figure 3.7).

D. Discussion
This work had two primary goals: [1] to characterize any metabolic differences
in NHERF1 KO mouse kidneys and [2] to evaluate if metabolic changes in
NHERF1 KO mouse kidneys could predispose these animals to susceptibility of
cisplatin-induced AKI. As discussed in the introduction, previous studies noted
metabolic changes in affected mouse kidneys post cisplatin treatment,
contributing to both injury and the development of CKD. These studies revealed
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Figure 3.7

Figure 3.7: ATP content of WT and NHERF1 KO mouse kidneys.
2-4 month old male C57BL/6J WT and NHERF1 KO mice kidneys were removed
and snap-frozen in liquid nitrogen. LC-MS was utilized to evaluate amount of
ATP in these tissues as described in Chapter II. Data are means ± SEM (WT
n=5) and (KO n=5). No significant differences were reported in these kidneys.
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that cisplatin nephrotoxicity depletes amino acids (86-89), reduces fatty acid
oxidation (86, 89, 91), reduces glycolytic enzymes (86, 93), and decreases
intermediates of the pentose phosphate pathway and the citric acid cycle (86,
94).
One of the first objectives of this study was to evaluate any changes in
gluconeogenesis of NHERF1 KO mouse kidneys compared to WT mouse
kidneys pre and post cisplatin treatment. Baseline measurements of FBPase
showed no changes in enzymatic activity with NHERF1 loss; furthermore, WT
and NHERF1 KO kidneys both had a decrease in activity following cisplatin
treatment. Indicating that FBPase functions similarly with or without NHERF1,
consistent with other reports (128, 129). Likewise, G6Pase activity was
unchanged with NHERF1 loss and, similarly to other reports, decreased after
cisplatin treatment in both genotypes (128, 129). These data confirm that
NHERF1 loss does not have an apparent effect on gluconeogenesis, whereas
cisplatin injury results in decreased gluconeogenic enzymes. MDH and LDH
belong to the same family of NAD-dependent enzymes, and cisplatin-induced
oxidative stress has been shown to increase LDH due to lipid peroxidation and
decrease MDH (130, 131). Interestingly, this study found no significant changes
in LDH and MDH activity regardless of genotype or cisplatin treatment, which is
consistent with a previous study that demonstrated similar results where LDH
and MDH activities were unchanged after cisplatin treatment in rats (132). These
disparities between studies and cisplatin’s effect on LDH and MDH activities
further illustrate the complexity of this disease.
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ME and G6PD activity provide necessary NADPH, a key cofactor in redox
control and reductive biosynthesis. ME plays a role in production of pyruvate and
serves as an additional source of NADPH for lipogenesis. Mammals that utilize
glucose for lipogenesis via citrate are believed to rely heavily on transferring
reducing equivalents from extra-mitochondrial NADH to NADP through the
combined acts of MDH and ME (134). Pyruvate from ME is available to re-enter
the mitochondria and be converted to of oxaloacetate or acetyl-CoA (134).
Additionally, there is recent evidence for direct cross-talk between ME and the
pentose phosphate pathway (135), where G6PD is a rate limiting enzyme.
Another goal of this study was to determine the effect of NHERF1 loss and/or the
combined effect with cisplatin on ME and G6PD activity. Notably, both ME and
G6PD activity were significantly increased in the NHERF1 KO mouse kidney
under baseline conditions. Following cisplatin treatment ME and G6PD activity
decreased until level with cisplatin treated WT activity and resulted in a
significant interaction. These increases in ME and G6PD activity at baseline
suggest some altered or compensatory metabolic changes in the pentose
phosphate pathway of NHERF1 KO mice. One study found using a cell culture
model of diabetes that increased activity of G6PD restored redox balance in
endothelial cells exposed to high glucose levels (136), where high glucose levels
had previously decreased G6PD and increased levels of oxidative stress.
Multiple studies have noted the importance of cellular redox balance in both
development of and in protection from renal injury (103, 104). In rats G6PD
activity is reported to decrease in acute models of nephrotoxicity, and ME activity
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is reported to increase (129). Additionally, one other investigator found that
NHERF1 is a previously unidentified regulator of Nox1 (NADPH oxidase) and
further promotes Nox1 activity (81). In fact, vascular smooth muscle cells
deficient of NHERF1 were unable to mount a ROS response to potent O 2 stimuli
(81). Taken together, one possible explanation for these data are that NHERF1
KO mice are under some stress resulting in an increase in G6PD activity in an
attempt to restore redox balance. Whether, redox balance is indeed restored in
these mice will be further investigated in Chapter V. These data suggest subtle
metabolic changes in the kidneys of the NHERF1 KO animals, but do not allow
us to make definitive conclusions on the mechanism involved. This is in part due
to the amelioration of cisplatin nephrotoxicity when antioxidants are given or
when there is a decrease in ROS prior to treatment. On the other hand, cisplatin
does decrease intermediates of the pentose phosphate pathway. Indicating this
could be a mechanism of enhanced susceptibility if the NHERF1 KO kidneys are
more reliant on this pathway for energy generation.
Lastly, this study evaluated ATP levels between WT and NHERF1 KO
kidneys to determine any alterations in cellular energy. Following LC-MS
assessment it was determined that WT and NHERF1 KO kidneys contain similar
levels of ATP, indicating that NHERF1 KO mice are not depleted and/or
producing higher amounts of ATP due to energy demands. Collectively, the
results of the ATP, G6PD and ME data point towards potential changes in
NADPH of NHERF1 KO mice. This presents another area of interest to
investigate in the future.
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In conclusion, this study provides insight into metabolic changes of NHERF1
KO mice. In this study increased enzymes of the pentose phosphate pathway
were found in NHERF1 KO mice and suggest these animals are expressing
some differences in metabolic pathways when compared to WT animals. The
basis for these changes in the activity of this metabolic pathway and its
significance for the increased susceptibility of NHERF1 KO mice to cisplatin
nephrotoxicity remain unknown. These results provide another avenue to be
explored in the future pertaining to NADPH levels in NHERF1 KO mouse
kidneys. Further investigation into bioenergetics of the NHERF1 KO mouse
kidneys may elucidate more insight into susceptibility to cisplatin injury.
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CHAPTER IV

MECHANISM OF SUSCEPTIBILITY OF NHERF1 KO MICE TO CISPLATININDUCED AKI IS NOT MITOCHODNRIAL DYSFUNCTION

A. Introduction
Mitochondria are important for multiple cellular functions but are more
commonly known as the ‘powerhouse of the cell’. In all eukaryotic cells that do
not undergo photosynthesis the mitochondria is the main source for ATP, an
energy rich compound that drives cellular functions (137, 138). The inner
mitochondrial membrane is the site of the ETC and oxidative phosphorylation
where ATP is generated from ADP and phosphate ions (137, 138). Other
mitochondrial functions apart from cellular respiration and ATP synthesis include:
production of NADH and GTP in the citric acid cycle, amino acid biosynthesis,
calcium signaling, stress responses, and cellular signaling (137, 138). On the
other hand, when mitochondria are damaged they undergo electron leakage and
produce massive amounts of free radicals in the form of ROS, leading to cell
injury and death. Thus, mitochondrial dysfunction is often the cause of severe
diseases.
Not surprisingly, the critical role of mitochondria in human health and disease
progression has strengthened interest in the relationship of mitochondrial
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function and cisplatin nephrotoxicity. As previously discussed in Chapters I and
III, cisplatin is a highly successful chemotherapeutic with nephrotoxic side
effects. This toxicity greatly limits cisplatin’s therapeutic use and often leads to
the development of AKI (8). Pathologically cisplatin induces cell death and injury
to the renal tubules, triggers vascular dysfunction, and launches a strong
inflammatory response (8). These effects of cisplatin result in both necrosis and
apoptosis in the proximal and distal tubules. Cisplatin’s mechanism of toxicity
remains uncertain to this day, however, cisplatin induced-mitochondrial
dysfunction and the development of renal tubule cell damage/death provides an
attractive hypothesis.
Cisplatin nephrotoxicity results in a decline in both state 3 mitochondrial
respiration and calcium accumulation (139-141). Additionally, cisplatin
nephrotoxicity has been associated with a decrease in cytochrome c oxidase
activity and a reduction in complex IV protein expression (139-142). These
changes can lead to increased ROS production from mitochondria. Moreover,
cisplatin toxicity drastically reduces renal cell antioxidant activity (139, 140, 142,
143). Some studies found that cisplatin-induced mitochondrial damage results in
a decrease in mitochondrial mass, disruption of cristae, and even mitochondrial
swelling (105, 139, 140). These morphological changes are associated with a
significant reduction in mitochondrial activity and ATP production (139, 140).
Furthermore, protein-bound platinum was found in renal tubule cell mitochondria
24 hours after cisplatin treatment (144). Together, these studies indicate a critical
role of mitochondrial function and oxidative stress in cisplatin nephrotoxicity.
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These studies provided a new avenue of research to explore in understanding
how NHERF1 loss increases susceptibility to cisplatin-induced AKI. In Chapter III
NHERF1 loss was associated with an increase in ME and G6PD activity under
baseline conditions and a differential response when compared to WT animals,
suggesting compensatory mechanisms that may affect mitochondrial function.
Previous studies from our laboratory comparing WT and NHERF1 deficient
opossum kidney (OK) cells, a model of mammalian renal proximal tubule,
demonstrated that the NHERF1 deficient cells grew more slowly and were more
likely to die in culture with no apparent morphological differences. Additionally,
proteomic studies revealed that NHERF1 KO mice exhibited markedly diminished
associated mitochondrial proteins in the BBM of these mice (unpublished data).
These properties of the NHERF1 deficient cells and mice (the poor survival,
decreased expression of mitochondrial proteins in BBM, and aberrant pentose
phosphate enzyme activity) suggested that NHERF1 loss may be associated with
mitochondrial dysfunction and susceptibility to kidney injury. Based on these
observations the goals of this work are twofold: [1] to determine if NHERF1 KO
mice have altered mitochondrial function and/or structure and [2] to determine if
NHERF1 KO mice have an underlying mitochondrial dysfunction that
predisposes these animals to cisplatin nephrotoxicity.

B. Experimental Procedures
1. Electron microscopy
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2-4 month old male WT and NHERF1 KO mice were perfused with 3%
glutaraldehyde and the kidneys were removed for EM analysis as described in
Chapter II.

2. Seahorse XF24 mitochondrial respiration analysis
Mitochondria were isolated from 2-4 month old male WT and NHERF1 KO
mouse kidney homogenates. Seahorse XF24 analysis of OCR of isolated
mitochondria were obtained as described in Chapter II.

3. Data analysis
EM and Seahorse XF24 mitochondrial data were analyzed as described in
Chapter II.

4. Statistical analysis
Statistical analysis of electron microscopy and Seahorse XF24 mitochondrial
data was performed as described in Chapter II.

C. Results
1. NHERF1 loss does not affect kidney proximal tubule mitochondria
morphology.
The mitochondrial structure is essential for proper function, thus, EM images
of WT and NHERF1 KO proximal tubule mitochondria were utilized to evaluate
their morphology as described in Chapter II. These images were taken and
evaluated by a renal pathologist for signs of injury, oxidative stress, and changes
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in cristae. There were no apparent changes in mitochondria morphology between
WT and NHERF1 KO proximal tubules (Figure 4.1). The only injury reported was
early ischemic changes mostly likely due to harvesting of the kidneys (Figure
4.1). Some endosomal swelling was noted but occurred across both genotypes.
Additionally, in figure 4.1 the density and distribution of mitochondria within the
tubules were also alike. Lastly, no apparent signs of oxidative stress were found
in either genotype (Figure 4.1).

2. NHERF1 loss does not affect mitochondria number or area in kidney
proximal tubules.
Changes in mitochondrial number and a decrease in size have been
associated with a decline in mitochondrial function (145). Therefore, one goal of
this study was to determine if mitochondrial number and/or size changed in
NHERF1 KO proximal tubules when compared to WT. Images from EM of WT
and NHERF1 KO kidney proximal tubules were utilized in order to count the
number of mitochondria and to calculate the average area via Image J. There
was not a significant difference between the average number of mitochondria
between WT and NHERF1 KO tubules (WT average number: 128.8) and
(NHERF1 KO average number: 115) (P = 0.6) (Figure 4.2A). In addition, there
was not a significant difference between the average area of mitochondria in WT
and NHERF1 KO tubules (WT average area: 580,540.9 μm2) and (NHERF1 KO
average area: 678,465.4 μm2) (P = 0.75) (Figure 4.2B).
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Figure 4.1

Figure 4.1: Electron microscopy of WT and NHERF1 KO proximal tubule
mitochondria.
Representative photomicrographs of a 4x field of WT and NHERF1 KO proximal
tubule mitochondria. The left panel represents proximal tubule mitochondria of
WT mice, while the right panel represents NHERF1 KO proximal tubule
mitochondria (WT n=6) and (NHERF1 KO n=5). The scale bars were set at 2 μm.
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Figure 4.2

Figure 4.2: Mitochondrial number and area of WT and NHERF1 KO mouse
proximal tubules.
2-4 month old male WT and NHERF1 KO mice were perfused with 3%
glutaraldehyde for EM analysis. (A) Number of mitochondria were counted in
random 4x visual fields with the highest density of mitochondria. Data are means
± SEM (WT n=6) and (NHERF1 KO n=5). Mitochondria number of NHERF1 KO
proximal tubules were insignificant when compared to WT. (B) Mitochondria area
was calculated using EM images and Image J. Data are means ± SEM (WT n=6)
and (NHERF1 KO n=5). Mitochondria area of NHERF1 KO proximal tubules were
insignificant when compared to WT.
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3. WT and NHERF1 KO mouse kidney mitochondria have similar
oxidative capacities.
The mitochondria’s capacity to reduce oxygen is a critical aspect in the
process of mitochondrial electron transport and ATP synthesis. Therefore,
measuring mitochondrial oxygen consumption can provide a valuable method to
assess mitochondrial function. One purpose of this work was to assess
mitochondrial function by oxidative capacity in WT and NHERF1 KO kidneys
using the Seahorse XF24 analyzer. In panel A of figure 4.3 OCR of WT and
NHERF1 KO kidney mitochondria are shown over time. Both WT and NHERF1
KO mitochondria exhibit a similar trend and response to added substrates and
inhibitors. When adding the substrate Succinate/Rotenone plus ADP for
production of ATP both genotypes exhibit a maximal increase in OCR. Moreover,
both genotypes undergo a decrease in OCR after adding Oligomycin, an inhibitor
of Complex V (formation of ATP from ADP via O2 consumption). Lastly,
Antimycin A shuts down all respiration, where the OCR is close to the basal
OCR. The difference between the basal OCR and OCR after Antimycin A is the
non-mitochondrial respiration.
Changes in state 3 (conversion of ATP from ADP and consumption of O2) and
state 4 (non-phosphorylating or resting respiration) respiration are commonly
used to evaluate mitochondria oxidative capacity. Panel B of figure 4.3 shows
both state 3 [(WT: 60 pmoles/min/μg protein ± 6) and (NHERF1 KO: 44

70

Figure 4.3
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Figure 4.3: Mitochondrial function in isolated mitochondria of WT and NHERF1
KO kidneys.
Mitochondria from 2-4 month old male WT and NHERF1 KO mice were isolated
and analyzed via the Seahorse XF24 for oxidative capacity as described in
Chapter II. (A) OCR was recorded after the addition of both substrates
(Succinate/Rotenone/ADP) and inhibitors (Oligomycin and Antimycin A) [(WT
n=6) and (NHERF1 KO n =6)]. (B) State 3 and State 4 was calculated using the
recorded OCR’s of WT and NHERF1 KO mitochondria. Data are means ± SEM
[(WT n=6) and (NHERF1 KO n=6)]. State 3 and State 4 respiration were
considered insignificant between WT and NHERF1 KO mouse kidney
mitochondria. (C) Respiratory control ratio (RCR) (state 3/state 4) was calculated
between WT and NHERF1 KO kidney mitochondria. Data are represented as
state 3/state 4 ratio [(WT n =6) and (NHERF1 n=6)]. RCR was insignificant
between WT and NHERF1 KO mouse kidney mitochondria.
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pmoles/min/μg protein ± 2)] and 4 [(WT: 37 pmoles/min/μg protein ± 6) and
(NHERF1 KO: 28 pmoles/min/μg protein ± 2)] of WT and NHERF1 KO kidney
mitochondria, where state 3 (P = 0.2) and 4 (P = 0.1) were determined to be
insignificant between the groups.
The respiratory control ratio (RCR) is the best general measure of
mitochondrial function in isolated mitochondria. RCR is measured by taking state
3/state 4 respiration and sums up the main function of mitochondria: the ability to
idle at low rates and then respond to ADP by making ATP at high rates. In
addition the RCR has no absolute value that is diagnostic of mitochondrial
dysfunction (146). Thus, RCR values are substrate and tissue dependent,
making this complex function advantageous when measuring mitochondrial
function in isolated mitochondria (146). A change in almost any aspect of
oxidative phosphorylation will result in a change in the RCR when comparing
isolated mitochondria (146). Accordingly, the RCR was calculated between WT
(1.63) and NHERF1 (1.61) KO kidney mitochondria and also found to be
insignificant (Figure 4.3C).

D. Discussion
The goal of this study was to determine if NHERF1 loss results in
mitochondrial dysfunction. This possibility was investigated as a potential
mechanism of susceptibility of NHERF1 KO mice to cisplatin-induced AKI. This is
the first study to investigate mitochondrial dysfunction in NHERF1 KO mice, and
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the first to show that NHERF1 KO mice do not have an underlying mitochondrial
dysfunction.
The morphology of proximal tubule mitochondria of WT and NHERF1 KO
mice was determined to be similar. Structural changes in mitochondria are
indicative of improper function thus; these observations indicate that NHERF1
KO mice proximal tubule mitochondria do not have structural changes leading to
dysfunction. In addition to structural changes, mitochondrial number and size
were also evaluated. With age, mitochondrial integrity and functionality are
known to decrease due to mutations and oxidative damage by ROS (145).
Moreover, in aged mice (22-28 months), mitochondria exhibit lowered oxidative
capacity, reduced oxidative phosphorylation, decreased ATP production,
significant increase in ROS generation, and diminished antioxidant defense (145,
147). In addition, with age mitochondrial biogenesis declines due to alterations in
mitochondrial dynamics and inhibition of mitophagy, an autophagy process that
removes dysfunctional mitochondria. Thus, one question postulated was if
NHERF1 KO mice had a change in mitochondrial number and/or area that would
indicate inadequate functioning or stress. EM analysis found that both
mitochondrial number and area were similar between both genotypes,
suggesting proper mitochondrial integrity and biogenesis in NHERF1 KO mice
proximal tubules.
Assessing mitochondrial dysfunction requires a definition of that dysfunction,
usually defined as the mitochondria’s capability of making ATP in response to
energy demands. Furthermore, this dysfunction can be evaluated in isolated
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mitochondria. For isolated mitochondria the best method of evaluating
dysfunction is analyzing mitochondrial oxidative capacity and respiratory control.
Respiratory control is the increase in respiration in response to ADP. The RCR is
both substrate and tissue dependent, however, when comparing different study
groups a high RCR value indicates good mitochondrial function, while a low RCR
indicates mitochondrial dysfunction. When comparing WT and NHERF1 KO
mitochondrial function state 3 and state 4 were determined to be similar between
the genotypes. Furthermore, the RCR (state 3/state 4) was determined to be the
same (NHERF1 KO: 1.61 vs WT: 1.63). These data indicate that NHERF1 KO
mouse kidney mitochondria are responding accordingly to energy demands when
isolated from tissue. However, isolated mitochondria removed from their natural
environment and the effect of the intracellular milieu on mitochondria function
cannot be assessed in this type of assay. Previous studies established that
NHERF1 KO mice exhibited phosphate wasting (148). This phenotype could
create an environment where mitochondria cannot function properly. When
isolating mitochondria both the isolation buffer and respiration buffer contain
phosphate to ensure the isolation process does not harm the mitochondria’s
ability to function. Therefore, a future project would be to evaluate mitochondrial
function using whole kidney tissue with the Seahorse XF24 analyzer. This
experiment could help clarify if NHERF1 KO mouse kidneys have an underlying
mitochondrial dysfunction due to their environment and hence serving to answer
the question if an underlying mitochondrial dysfunction could predispose
NHERF1 KO mice to cisplatin nephrotoxicity.
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This study demonstrates that proximal tubule mitochondria from NHERF1 KO
kidneys are structurally similar and healthy when compared to WT mitochondria.
Additionally, isolated mitochondria from NHERF1 KO mice do not exhibit
changes in function indicative of stressed or dysfunctional kidney mitochondria.
These data do not support the hypothesis that NHERF1 loss results in an
underlying mitochondrial dysfunction. However, one potential mechanism that
has yet to be investigated is whether NHERF1 loss and the subsequent low
phosphate environment affects kidney mitochondrial function. This information
may provide an alternative mechanism of susceptibility to cisplatin nephrotoxicity
in NHERF1 KO mice, and it will be investigated in the future. Understanding the
underlying mechanism of susceptibility to cisplatin-induced AKI with NHERF1
loss may provide future therapeutic targets and or biomarkers to use in the clinic.
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CHAPTER V

NHERF1 LOSS AFFECTS GGT ACTIVITY IN RESPONSE TO CISPLATIN

A. Introduction
Cisplatin is one of the most effective chemotherapeutic agents used to treat a
number of diseases including: head and neck, esophageal, bladder, testicular,
ovarian, uterine, cervical, breast, stomach, small cell, and non-small cell lung
cancer (8-10). As a chemotherapeutic cisplatin crosslinks with purine bases in
DNA and inhibits DNA synthesis (9). Because cisplatin shows its highest activity
in highly proliferative cells, its unusual dose-dependent and cumulative side
effect of nephrotoxicity remains a mystery (8-10). In addition, some patients
appear to have an increased sensitivity to this side effect, with 20-30%
developing cisplatin-induced AKI with a single dose (8). This sensitivity remains
an important area of research as there are no FDA-approved strategies or
approved therapies for preventing or ameliorating cisplatin-induced AKI.
In hopes of tackling this urgent clinical need, much research has been driven
in understanding how cisplatin is handled by the kidneys. To date the accepted
hypothesis for the renal handling of cisplatin is that during glomerular filtration
cisplatin accumulates in the kidneys (149). OCT2 and Ctr1 have been identified
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as membrane transporters capable of cisplatin uptake in renal proximal tubule
cells (150). Furthermore, MATE1 has also been identified in transporting cisplatin
from the proximal tubule to the urine (22). Cisplatin nephrotoxicity was
ameliorated with OCT2 inhibition and is exacerbated with MATE1 inhibition in
mice (18, 22, 150). Biotransformation of cisplatin is believed to start immediately
after transportation into the apical renal epithelial cell (25). The initial
biotransformation step is proposed to be with the formation of glutathione
conjugates (25). These conjugates are then cleaved to cysteinyl-glycineconjugates by GGT, which is expressed on the surface of proximal tubule cells
(25). From there AP is thought to convert cysteinyl-glycine-conjugates to cysteine
conjugates, which are then believed to be further metabolized by CCBL into
highly reactive nephrotoxic thiols (25). With that series in mind, much of the
biotransformation of cisplatin in the kidney remains controversial. For example, it
is known that GGT has the highest activity in the kidney and it was thus
considered a potential target for attenuation of nephrotoxicity. However,
investigation into that possibility yields controversial results, suggesting that
enhanced GGT activity may either increase or decrease sensitivity to cisplatininduced AKI (151).
These conflicting results have made the development of reno-protective
strategies or therapies difficult. Recently, a new potential target, NHERF1, a
known scaffolding protein important to the proper function of renal proximal
tubule cells, has been identified. In this recent study NHERF1 KO mice exhibited
exacerbated cisplatin nephrotoxicity, manifested by a significant increase in BUN,

78

NGAL, and higher histologic injury severity scores than in cisplatin treated WT
mice (35). Interestingly, NHERF1 KO mice showed similar levels of apoptosis
when compared to WT mice, but had a clear increase in necrotic cell death
following cisplatin treatment (35). Other studies noted that cisplatin nephrotoxicity
was dose dependent and involved both necrosis and apoptosis, however, higher
levels of necrosis were associated with higher concentrations of cisplatin (152,
153). Collectively, these data along with another study showing NHERF1
expression was also involved with cisplatin resistance in cervical cancer cells
(110), suggested that loss of NHERF1 may affect the renal handling of cisplatin.
The goal of this work was to elucidate new potential mechanisms of
susceptibility to cisplatin-induced AKI. NHERF1 loss was hypothesized to affect
the renal handling of cisplatin by alterations in renal uptake and/or metabolism. In
this endeavor the current understanding of cisplatin’s uptake and
biotransformation was utilized to evaluate NHERF1’s effect on cisplatin-induced
AKI.

B. Experimental Procedures
1. Animals and treatments
Male (2-4 month) WT and NHERF1 KO mice were treated with cisplatin (20
mg/kg IP) for 4, 24, or 72 hours as described in Chapter II.

2. γ-Glutamyl Transferase activity assay
The GGT activity assay was performed as described in Chapter II.
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3. Histology and immunohistochemistry
H&E, PAS, and IHC were performed as described in Chapter II.

4. NGAL
NGAL was determined as described in Chapter II.

5. TBARS
TBARS assay was performed as described in Chapter II.

6. HPLC
Blood and tissue samples for GSH, GSSG, Cys, CySS were processed and
analyzed as described in Chapter II.

7. Immunoblots
Western blots were performed as described in Chapter II.

8. Data analysis
Data analysis was performed as described in Chapter II.

10. Statistical analysis
Statistical analysis was performed as described in Chapter II.

C. Results
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1. NHERF1 loss results in early cisplatin-induced renal histologic injury.
H&E and PAS staining of the kidneys of cisplatin treated mice after 24 hours
revealed that NHERF1 KO mice exhibited early histologic injury that does not
correspond with treated WT mice at the same time point (Figure 5.1). Similarly to
the 72 hour time point, the injury is predominantly cortical in NHERF1 KO mice at
24 hours. This injury was manifested by intermittent casts, atrophy, and BBM
sloughing (Figure 5.1) in NHERF1 KO mice, while cisplatin treated WT mice
exhibited no obvious signs of histologic damage.

2. Cisplatin treatment significantly increases urine NGAL protein in
NHERF1 KO mice in comparison to cisplatin treated WT mice at 24
hours.
In order to confirm cisplatin treatment resulted in early higher kidney injury in
NHERF1 KO mice urine NGAL was measured as described in Chapter II. With
cisplatin treatment both WT (0.1 μg/mL ± 0.02) and NHERF1 KO (0.7 μg/mL ±
0.2) mice had a significant increase in NGAL protein compared to vehicle treated
WT (0.04 μg/mL ± 0.03) and NHERF1 KO (0.02 μg/mL ± 0.006) (P = 0.007)
(Figure 5.2). However, a statistically significant increase in NGAL urine protein
level was observed in cisplatin treated NHERF1 KO compared to cisplatin treated
WT mice (P = 0.03) (Figure 5.2). Additionally, a significant decrease in NGAL
urine protein in vehicle treated NHERF1 KO compared to vehicle treated WT
mice was found (P = 0.04) (Figure 5.2).
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Figure 5.1

Figure 5.1: Early histologic effect of cisplatin on WT and NHERF1 KO kidneys.
Representative photomicrographs (40x) of H&E (top panel) and PAS staining
(bottom panel) of 24 hour cisplatin treated WT and NHERF1 KO mice. H&E
panel (A) represents a vehicle treated WT kidney, (B) a vehicle treated NHERF1
KO kidney, (C) a cisplatin treated WT kidney, and (D) a cisplatin treated NHERF1
KO kidney. PAS panel (A) and (C) represent cisplatin treated WT kidneys and
panel (B) and (D) represent cisplatin treated NHERF1 KO kidneys. Arrows
indicate areas of injury (casts and BBM sloughing).
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Figure 5.2

Figure 5.2: Effect of cisplatin on urine NGAL.
NGAL protein measurement of mouse urine in 24 hour cisplatin treated WT and
NHERF1 KO mouse kidneys. Data are means ± SEM (WT vehicle: n=5),
(NHERF1 KO vehicle: n=5), (WT cisplatin: n=7), and NHERF1 KO cisplatin: n=8).
**P = 0.007 cisplatin treated WT and NHERF1 KO mice compared to vehicle
saline controls; *P = 0.03 cisplatin treated NHERF1 KO compared to cisplatin
treated WT mice; *P = 0.04 vehicle treated NHERF1 KO mice compared to
vehicle treated WT mice.
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3. NHERF1 loss does not affect lipid peroxidation by TBARS
Cisplatin nephrotoxicity has been shown in rats to induce lipid peroxidation,
oxidative degeneration on lipids in cellular membranes (120). A TBARS assay
was utilized to test if NHERF1 loss alone led to lipid peroxidation or if cisplatin
treated NHERF1 KO mice had an increased level of lipid peroxidation. The
TBARS assay measures levels of malondialdehyde (MDA) and other lipid
peroxidation products. WT and NHERF1 KO 72 hour cisplatin treated kidney
cortex homogenates were used for this assay. Under baseline conditions lipid
peroxidation levels were similar for both genotypes (WT vehicle: 0.95 nmole/mg
± 0.09) and (NHERF1 KO vehicle: 0.96 nmole/mg ± 0.09) (Figure 5.3). No
significant increase of lipid peroxidation was found with cisplatin treatment in
either WT (0.86 nmole/mg ± 0.05) or NHERF1 KO (0.83 nmole/mg ± 0.07) mice
(Figure 5.3). Furthermore, no differences were found between cisplatin treated
WT and NHERF1 KO mice (Figure 5.3).

4. NHERF1 loss increases 4-hydroxynonenal in cortex and
juxtamedullary region following cisplatin treatment
Besides MDA, 4-hydroxynonenal (4-HNE) is another product of lipid
peroxidation. To give a broader view of lipid peroxidation in vehicle and cisplatin
treated mice IHC of 4-HNE was performed. IHC for 4-HNE showed minimal
staining with no marked differences between genotypes for vehicle treated
kidneys (Figure 5.4). Cisplatin treatment resulted in an increase in 4-HNE
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Figure 5.3

Figure 5.3: Cisplatin’s effect on lipid peroxidation by TBARS in WT and NHERF1
KO mice.
TBARS measurement of lipid peroxidation of kidney cortex 72 hour cisplatin
treated WT and NHERF1 KO mice. Data are means ± SEM (WT vehicle: n=5),
(NHERF1 KO vehicle: n=5), (WT cisplatin: n=8), and NHERF1 KO cisplatin: n=9).
No significant differences were found between treatment groups.
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Figure 5.4

Figure 5.4: The effect of NHERF1 loss and cisplatin treatment on 4-HNE staining
in the kidney.
Representative photomicrographs (10x) of IHC staining of 4-HNE in 72 hour
cisplatin treated WT and NHERF1 KO mice. Panel (A) represents a vehicle
treated WT kidney, (B) a vehicle treated NHERF1 KO kidney, (C) a cisplatin
treated WT kidney, and (D) a cisplatin treated NHERF1 KO kidney. Arrows
indicate areas of marked staining in the cortex and juxtamedullary (JM) region of
the kidney.
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staining within the cortex and juxtamedullary (JM) region of both genotypes,
however, staining was more marked in the cisplatin treated NHERF1 KO kidneys,
especially in the JM regions (Figure 5.4).

5. NHERF1 KO kidneys do not have altered GSH metabolism
Cisplatin nephrotoxicity is proposed to deplete GSH and to induce oxidative
stress resulting in cellular injury and death. Due to this finding, HPLC of the
reduced and oxidized forms of small molecular weight thiols, GSH, glutathione
disulfide (GSSG), cysteine (Cys) and cystine (CySS), and the mixed disulfide
between the two, cysteine-glutathione disulfide (CySSG), were performed on
plasma and kidney cortex 72 hours after cisplatin treatment. In vehicle treated
mice, the only significant difference observed in plasma was a CySS decrease in
NHERF1 KO (24.1 µM ± 3.7) relative to WT (37.6 µM ± 2.7) (P = 0.0042) (Figure
5.5 A). Additionally, after cisplatin treatment NHERF1 KO mice (18.9 µM ± 3.2)
had a decrease in plasma CySS compared to WT (29 µM ± 4) (P = 0.0042)
(Figure 5.5 A). In response to cisplatin, plasma CySS, Cys [(WT vehicle: 29 µM ±
3), (NHERF1 KO vehicle: 31 µM ± 2), (WT cisplatin: 23 µM ± 3), (NHERF1 KO
cisplatin: 20 µM ± 2)] (P = 0.013), CySSG [(WT vehicle: 22 µM ± 3), (NHERF1
KO vehicle: 21 µM ± 6), (WT cisplatin: 16 µM ± 1), (NHERF1 KO cisplatin: 10 µM
± 2)] (P = 0.003), GSH [(WT vehicle: 30 µM ± 3), (NHERF1 KO vehicle: 35 µM ±
2), (WT cisplatin: 23 µM ± 2), (NHERF1 KO cisplatin: 24 µM ± 4)] (P = 0.02), and
GSSG [(WT vehicle: 5 µM ± 1), (NHERF1 KO vehicle: 7 µM ± 2), (WT cisplatin: 3
µM ± 0.3), (NHERF1 KO cisplatin: 3 µM ± 0.6)] (P = 0.002) decreased when
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Figure 5.5
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Figure 5.5: Cisplatin and NHERF1 loss effect on small molecular weight thiols.
Plasma and Kidney GSG, GSSG, CySSG, Cys, and CySS were measured in 72
hour vehicle and cisplatin treated WT and NHERF1 KO mice. Data are means ±
SEM. Plasma: (WT vehicle: n=5), (NHERF1 KO vehicle: n=5), (WT cisplatin:
n=7), and (NHERF1 KO cisplatin: n=9) and Kidney: (WT vehicle: n=5), (NHERF1
KO vehicle: n=5), (WT cisplatin: n=8), and (NHERF1 KO cisplatin: n=9). Plasma:
*P < 0.05 cisplatin treated WT and NHERF1 KO mice compared to vehicle saline
controls for CySS, Cys, CySSG, GSH, GSSG, and CySSG; *P < 0.05 vehicle
treated NHERF1 KO compared to vehicle treated WT mice for CySS. Kidney: *P
< 0.05 vehicle treated NHERF1 KO mice compared to vehicle treated WT mice
for CySS, Cys, and GSSG; *P < 0.05 cisplatin treated WT and NHERF1 KO mice
compared to vehicle saline controls for CySS, Cys, CySSG, and GSSG.
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Table 5.1:
Oxidized and Reduced
forms

CyS
CySS
CySSG
GSH
GSSG
GSH/GSSG

WT
veh
↑
↑
↑
↑
↑
N/A

Plasma
KO WT
veh cis
↑
↓
↓
↑
↑
↓
↑
↓
↑
↓
N/A N/A

KO
cis
↓
↓
↓
↓
↓
N/A

WT
veh
↑
↑
↑
NS
↓
↑

Kidney
KO WT
veh cis
↓
↑
↓
↑
↑
↓
NS
NS
↑
↓
↓
↑

KO
cis
↑
↑
↓
NS
↓
↑

Table 5.1: Summary of the effect of NHERF1 and cisplatin on small molecular
weight thiols.
Plasma and Kidney GSG, GSSG, CySSG, Cys, and CySS were measured in 72
hour vehicle and cisplatin treated WT and NHERF1 KO mice. Table 5.1
illustrates the summarized effects of NHERF1 and cisplatin treatment on CyS,
CySS, CySSG, GSH, GSSG, and GSH/GSSG in both the plasma and the kidney.
N/A stands for not applicable and NS for not significant. Arrows indicate
increased or decreased levels of each small molecular weight thiol.
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compared to vehicle treated mice (Figure 5.5A & B). In the kidney vehicle treated
NHERF1 KO mice had a decrease in Cys (3 nmole/mg protein ± 2) (P = 0.03)
and an increase in GSSG (2 nmole/mg protein ± 0.1) (P = 0.022) relative to
vehicle treated WT mice [(CySSG: 15 nmole/ mg protein ± 1), (Cys: 5 nmole/ mg
protein ± 0.2), (GSSG: 1 nmole/mg protein ± 0.1) (Figure 5.5 C & D). Cisplatin
treatment led to an increase in CySS [(WT cisplatin: 1 nmole/mg protein ± 0.1),
(NHERF1 KO cisplatin: 0.8 nmole/mg protein ± 0.08)] (P = 0.002) and Cys [(WT
cisplatin: 9 nmole/mg protein ± 1), (NHERF1 KO cisplatin : 7 nmole/mg protein ±
0.8)] (P = 0.0005) and a decrease in CySSG [(WT cisplatin: 3 nmole/mg protein ±
0.4), (NHERF1 KO cisplatin: 3 nmole/mg protein± 0.7)] (P < 0.0001) and GSSG
[(WT cisplatin: 0.7 nmole/mg protein ± 0.1), (NHERF1 KO cisplatin: 0.8 nmole/mg
protein ± 0.08)] (P < 0.0001) in both genotypes (Figure 5.5 C & D). On the other
hand, cisplatin did not affect the kidney levels of GSH [(WT vehicle: 30 nmole/mg
protein ± 2), (NHERF1 KO vehicle: 27 nmole/mg protein ± 1), (WT cisplatin: 26
nmole/mg protein ± 3), (NHERF1 KO cisplatin: 24 nmole/mg protein ± 2)] in
either genotype (Figure 5.5 D). Kidney redox potential (GSH/GSSG) was also
measured and found to be increased in both genotypes with cisplatin treatment
[(WT vehicle: 26.4 ± 1.4), (NHERF1 KO vehicle: 18 ± 0.7), (WT cisplatin: 40.2 ±
4), and (NHERF1 KO cisplatin: 29.2 ± 2)] (P = 0.0002) (Figure 5.5 E).
Furthermore, NHERF1 KO kidneys were found to have a decrease in
GSH/GSSG redox potential under baseline (P = 0.003) (Figure 5.5 E).

6. NHERF1 loss affects GGT activity response to cisplatin insult
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Although controversial, GGT activity is thought to be part of cisplatin’s
biotransformation into a nephrotoxin. Urine GGT activity was found to be highest
after cisplatin treatment at 24 hours or earlier in humans (154). To understand
the effect NHERF1 loss has on GGT activity in response to cisplatin over time 4
hr and 24 hr cisplatin treated WT and NHERF1 KO kidneys were evaluated. GGT
activity was found to be non-significantly altered with NHERF1 loss alone at any
timepoint [4hr (WT vehicle: 5800 nmole/min/mL ± 1300), (NHERF1 KO vehicle:
5700 nmole/min/mL ± 1600)] and [24 hr (WT vehicle: 8100 nmole/min/mL ±
2300), (NHERF1 KO vehicle: 7200 nmole/min/mL ± 1500)], and remained similar
4 hours after cisplatin treatment [4 hr (WT cisplatin: 7000 nmole/min/mL ± 1600),
(NHERF1 KO cisplatin: 5300 nmole/min/mL ± 1600)] (Figure 5.6). However, 24
hours after cisplatin treatment there was a significant genotype difference
between WT and NHERF1 KO kidneys in response to cisplatin [24 hr (WT
cisplatin: 9900 nmole/min/mL ± 2400), (NHERF1 KO cisplatin: 7300
nmole/min/mL ± 1400)] (P = 0.04) (Figure 5.6).

7. NHERF1 loss does not affect GGT protein expression
To evaluate if NHERF1 loss affected the amount of GGT protein a western
blot was performed on the 4 and 24 hour cisplatin treated WT and NHERF1 KO
kidney homogenates (Figure 5.7). GGT protein expression was found to be
unchanged with NHERF1 loss under baseline conditions for either time point [4
hr (WT vehicle: 0.84 GGT/GAPDH ± 0.05), (NHERF1 KO vehicle: 0.62
GGT/GAPDH ± 0.08)] and
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Figure 5.6

Figure 5.6: Effect of NHERF1 on GGT activity following cisplatin treatment.
GGT activity was measured at 4 hours and 24 hours after cisplatin treatment in
WT and NHERF1 KO kidney cortex homogenates as described in Chapter II.
Data are means ± SEM. 4 hours: (WT vehicle: n=6), (NHERF1 KO vehicle: n=6),
(WT cisplatin: n=6), and (NHERF1 KO cisplatin: n=6) and 24 hours: (WT vehicle:
n=5), (NHERF1 KO vehicle: n=5), (WT cisplatin: n=7), and (NHERF1 KO
cisplatin: n=8). *P < 0.04 cisplatin treated NHERF1 KO compared to cisplatin
treated WT.
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Figure 5.7

Figure 5.7: Effect of NHERF1 loss on GGT protein.
Representative blots of 4 hour (A) and 24 hour (B) GGT and GAPDH are shown.
Kidney cortex homogenates were separated by 10% SDS-PAGE and transferred
to nitrocellulose membranes. Quantitation was performed as described in
Chapter II (B) Data are means ± SEM (WT vehicle: n=3), (NHERF1 vehicle: n=3),
(WT cisplatin: n=4), and (NHERF1 KO cisplatin: n=4). A representative blot from
2 independent experiments for each time point is shown.
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[24 hr (WT vehicle: 1.3 GGT/GAPDH ± 0.14), (NHERF1 KO vehicle: 1.2
GGT/GAPDH ± 0.1)] (Figure 5.7).Following cisplatin the amount of GGT protein
was also found to be unchanged at 4 and 24 hours post treatment in both
genotypes [4 hr (WT cisplatin: 0.7 GGT/GAPDH ± 0.09), (NHERF1 KO cisplatin:
0.9 GGT/GAPDH ± 0.03)] and [24 hr (WT cisplatin: 1.2 GGT/GAPDH ± 0.13),
(NHERF1 KO vehicle: 0.9 GGT/GAPDH ± 0.2)] (Figure 5.7).

8. GGT localization is altered in NHERF1 KO kidneys 24 hours after
cisplatin treatment
To evaluate localization of GGT in WT and NHERF1 KO kidneys, kidney
slices were stained for GGT by IHC. IHC revealed similar GGT staining in the
proximal tubules of both vehicle treated genotypes (Figure 5.8, panel A & B). In
cisplatin treated WT kidneys there was no apparent damage and GGT
localization remained unaltered (Figure 5.8, panel C). However, in the cisplatin
treated NHERF1 KO kidneys areas of BBM sloughing in the proximal tubule
showed decreased staining for GGT (Figure 5.8, panel D).

9. NHERF1 loss does not affect CCBL protein
CCBL is a pyridoxal phosphate-dependent enzyme that metabolizes Scysteine conjugates through transamination or β-elimination reactions, and is
also proposed to be involved in cisplatin’s biotransformation into a nephrotoxin.
To determine if there were any changes in CCBL protein in WT and NHERF1 KO
mice 4 hour and 24 hour cisplatin treated kidney cortex
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Figure 5.8

Figure 5.8: GGT localization in vehicle and cisplatin treated kidneys.
Representative photomicrographs (40x) of IHC staining of GGT in 24 hour
cisplatin treated WT and NHERF1 KO mice. Panel (A) represents a vehicle
treated WT kidney, (B) a vehicle treated NHERF1 KO kidney, (C) a cisplatin
treated WT kidney, and (D) a cisplatin treated NHERF1 KO kidney. Arrows
indicate areas of BBM sloughing and GGT staining loss.
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homogenates were analyzed via western blot. CCBL protein was found to be
unchanged with NHERF1 loss under baseline conditions for either time point [4
hr (WT vehicle: 1.4 CCBL/GAPDH ± 0.3), (NHERF1 KO vehicle: 1.1
CCBL/GAPDH ± .01)] and [24 hr (WT vehicle: 2.5 CCBL/GAPDH ± 0.7),
(NHERF1 KO vehicle: 1.2 CCBL/GAPDH ± 0.1)] (Figure 5.9). Following cisplatin
the amount of CCBL protein was also found to be unchanged at 4 and 24 hours
post treatment in both genotypes [4 hr (WT cisplatin: 1.7 CCBL/GAPDH ± 0.1),
(NHERF1 KO cisplatin: 1.3 CCBL/GAPDH ± 0.2)] and [24 hr (WT cisplatin: 2.2
CCBL/GAPDH ± 0.4), (NHERF1 KO cisplatin: 2.4 CCBL/GAPDH ± 0.8)] (Figure
5.9).

D. Discussion
The purpose of this study was to determine if NHERF1 loss affected the renal
handling of cisplatin. This possibility was investigated as a potential mechanism
of susceptibility of NHERF1 KO mice to cisplatin-induced AKI. This is the first
study to investigate the effect NHERF1 loss has on cisplatin uptake and/or
metabolism in the kidney as well as the first study to show an altered GGT
activity in response to cisplatin in NHERF1 KO mice.
NHERF1 KO mice are indeed more sensitive to cisplatin as confirmed by
earlier signs of cisplatin related kidney injury. WT mice did not show histologic
signs of injury 24 hours after cisplatin treatment. Additionally, WT mice had a
moderate increase in urine NGAL, a sensitive marker of kidney injury, 24 hours
after treatment. On the other hand, NHERF1 KO mice showed patchy areas of
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Figure 5.9

Figure 5.9: Effect of NHERF1 loss on CCBL protein.
Representative blots of 4 hour (A) and 24 hour (B) CCBL and GAPDH are
shown. Kidney cortex homogenates were separated by 10% SDS-PAGE and
transferred to nitrocellulose membranes. Quantitation was performed as
described in Chapter II (B) Data are means ± SEM (WT vehicle: n=3), (NHERF1
vehicle: n=3), (WT cisplatin: n=4), and (NHERF1 KO cisplatin: n=4). A
representative blot from 2 independent experiments for each time point is shown.
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histologic injury 24 hours after cisplatin administration (e.g. BBM sloughing,
casts, and atrophy). Moreover, NHERF1 KO mice had a robust increase in urine
NGAL 24 hours following cisplatin treatment. These data corroborate the
increased sensitivity to cisplatin seen in the previous 72 hour study (35). In
addition to evaluating the sensitivity of NHERF1 KO mice to cisplatin, levels of
lipid peroxidation were also measured.
Cisplatin has been shown to increase lipid peroxidation due to induced
oxidative stress. In this study a TBARS assay was utilized and WT and NHERF1
KO mice were found to have similar levels of lipid peroxidation via MDA. These
data illustrate the perplexing nature of cisplatin nephrotoxicity, where much of the
research is contradictory. In this study kidney cortex was used for the sample
preparation, however, other studies used whole kidney or did not clarify whether
cortex was isolated (155, 156). Conceivably these conflicting results may be due
to what area of the kidney was used, especially since IHC of 4-HNE revealed that
NHERF1 KO mice had an increased positive staining in both cortex and the JM
region. On the other hand, many of the lipid peroxidation studies were performed
on rats, while studies on mice seem to be dependent on the concentration of
cisplatin, dosing regimen, and mouse strain (116, 156, 157). In addition, rats are
more sensitive to cisplatin nephrotoxicity than mice (116). Thus, cisplatin
nephrotoxic cell death and the relationship to induced lipid peroxidation remains
obscure. However, both the TBARS assay and the IHC data reinforce that
NHERF1 KO mice do not have an underlying increase in lipid peroxidation.
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Therefore, this is not a mechanism of susceptibility of NHERF1 KO mice to
cisplatin-induced AKI.
Even though there was no apparent increase in lipid peroxidation other
indicators of oxidative stress were measured. These indicators included the
oxidized and reduced forms of small molecular weight thiols that act as
antioxidants. Plasma from 72 hour cisplatin treated mice showed a consistent
decrease in GSH, GSSG, CySSG, Cys, and CySS. These data are consistent
with other reports (25, 158-160). When compared to WT alone, NHERF1 loss led
to a decrease in cystine (CySS), which is the oxidized form of cysteine. CySS is
readily taken up into cells to be reduced to Cys. Cys is a necessary substrate for
the cellular antioxidant GSH (161). Although plasma CySS is decreased in the
vehicle treated NHERF1 KO mice GSH in the kidney remains similar between
vehicle treated WT and NHERF1 KO mice. Like in other studies, the kidney
CySSG and GSSG are decreased in both genotypes with cisplatin treatment, but,
unexpectedly GSH was not decreased in either genotype (159). The oxidized
form of glutathione (GSSG), was increased in the kidney of vehicle treated
NHERF1 KO mice. Collectively, NHERF1 KO mice had a decrease in CySS in
the plasma and an increase in GSSG in the kidney. Moreover, NHERF1 KO mice
had a decrease in kidney redox potential (GSH/GSSG) when compared to WT.
Perhaps these data indicate a low level of oxidative stress or maybe a
suppressed ability to convert CySS to Cys and GSSG to GSH with NHERF1 loss.
However, NHERF1 KO kidneys do not reflect a decrease in GSH levels.
Therefore, it appears that NHERF1 loss does not affect GSH metabolism itself.
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Unfortunately, the role of NHERF1 loss and an underlying oxidative stress
remains ambiguous as a potential mechanism. In the future measuring
glutathione peroxidase, glutathione synthase, superoxide dismutase or catalase
in WT and NHERF1 KO mice may be beneficial.
In addition to GSH metabolism and oxidative stress indicators, GGT activity
was also measured. Several studies have indicated GGT activity and/or
expression is important to the biotransformation of cisplatin to a nephrotoxin (13,
25, 26). A robust increase in GGT activity was seen in the 24 hour cisplatin
treated WT mice, while an increase in GGT activity was not seen in the NHERF1
KO mice, making it appear that they are unable to respond to cisplatin in this
manner and suggesting that NHERF1 is important for GGT’s response to an
insult. The role of GGT activity or expression in protection or susceptibility to
cisplatin nephrotoxicity is also controversial (113, 151). GGT KO mice are
protected from cisplatin nephrotoxicity (112). Alternatively, depending on the cell
type an increase in GGT activity may be protective or increase sensitivity to the
drug (151, 162). These data have led to two alternative theories: [1] GGT is
important in the conversion of cisplatin to a nephrotoxin thus inhibition leads to
protection or [2] GGT is important for detoxification of xenobiotics and production
of GSH, thus increased activity results in increased GSH production that can
alleviate some of the induced oxidative stress from cisplatin. The second theory
may explain the exacerbated AKI in NHERF1 KO mice. If NHERF1 loss limits the
ability of GGT to respond quickly and/or robustly to an insult there may be
increased injury. Besides evaluating GGT activity, protein levels and localization
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were investigated. GGT protein levels were not significantly different, however,
IHC showed some GGT loss in the proximal tubule due to BBM sloughing. This
GGT loss has been recorded in mice treated with cisplatin for 72 hours in
addition to a decrease in GGT activity at 72 hours (116, 154, 163). This
observation provides an alternative hypothesis for the difference in GGT activity
between WT and NHERF1 KO mice. Because NHERF1 KO mice are beginning
to lose GGT through BBM sloughing perhaps this is affecting their level of GGT
activity in response to cisplatin. Alternatively, a 12 hour time point may be useful
to determine if NHERF1 KO mice have an increase in activity between 4 and 24
hours post cisplatin treatment. This proposal would fall under the hypothesis that
an increase in GGT activity leads to worse injury. Thus, NHERF1 KO mice could
have an increase in GGT activity earlier and subsequently result in increased
damage by 24 hours. In any case more research is needed to understand how
cisplatin causes nephrotoxicity and what role GGT plays in that mechanism.
CCBL is the rate limiting enzyme in the production of the ‘reactive thiol’ in
cisplatin nephrotoxicity (13, 25-27). Understanding the effect of NHERF1 loss on
CCBL protein level, localization, and activity level are valuable pieces of
information. In this work CCBL protein level was investigated and found to be
similar regardless of genotype or treatment. Future experiments will also
evaluate CCBL activity and localization between vehicle and cisplatin treated WT
and NHERF1 KO mice. In addition to CCBL, determining platinum (Pt) levels in
cisplatin treated WT and NHERF1 KO mice is imperative. A change in Pt levels
between cisplatin treated WT and NHERF1 KO mice would be indicative of either
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altered uptake or extrusion of cisplatin. Blocking of the extrusion transport
protein, MATE1, results in increased toxicity from cisplatin (22). Moreover,
increased uptake and increased cisplatin concentrations led to worse damage
and an increase in necrosis (28, 116). Previously, 72 hour cisplatin treated
NHERF1 KO mice had an increase in ATN when compared to treated WT mice
(35). Thus, these data could suggest higher levels of cisplatin in these kidneys.
72 hour and 24 hour cisplatin treated kidneys have been sent for ICP-MS
analysis for Pt levels. This future data could provide more insight into the
exacerbated AKI of NHERF1 KO mice.
Ultimately, the mechanism of cisplatin nephrotoxicity remains a mystery,
however, it is evident that NHERF1 expression has a vital role in its
development. Until the other areas discussed (CCBL localization, activity, and Pt
levels) have been investigated the underlying mechanism of susceptibility to
cisplatin in NHERF1 KO mice remains unclear. These future experiments are
integral in elucidating the mechanism of susceptibility. Continued research and
broadening the understanding of cisplatin nephrotoxicity and susceptibility is an
encouraging area for the development of new innovative preventative protocols
or even therapeutic targets that can be used in the clinic.
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CHAPTER VI

DISCUSSION AND CONCLUSIONS

A. Restatement of goals and questions
The overall goal of the work described in this dissertation was to discover new
potential mechanisms and hypotheses for susceptibility to cisplatin-induced AKI
with NHERF1 loss. The work summarized in Chapter III aimed to test if metabolic
changes played a role in the sensitization of the NHERF1 KO mouse kidney to
cisplatin insult. Chapter IV aimed to evaluate if NHERF1 KO mice had an
underlying mitochondrial dysfunction due to: [1] decreases in mitochondrial
oxidative capacity and/or alterations in the structure of NHERF1 KO kidneys [2]
decreases in number of mitochondria in NHERF1 KO kidneys. Finally, Chapter V
of this dissertation used the proposed mechanism of cisplatin biotransformation
to a nephrotoxin to test if NHERF1 loss resulted in altered renal handling of
cisplatin. Taken together, these studies provide new insight into the mechanism
of susceptibility of NHERF1 loss in cisplatin-induced AKI.

B. Major findings of this dissertation
1. NHERF1 loss results in altered pentose phosphate enzymes in mice
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The accumulation and bioactivation of cisplatin to a nephrotoxic metabolite
has been extensively studied, but requires further clarification for the
development of novel therapeutic targets or prevention protocols to be used in
the clinic. Recent studies have found that cisplatin alters renal cell metabolism,
contributing to injury and the secondary result of CKD development. These
studies have provided a new avenue of research for cisplatin-induced AKI
development. Cisplatin treatment results in depletion of amino acids in the kidney
(86-89), reduces fatty acid oxidation while concomitantly accumulating fatty acids
in the kidney (86, 89, 91), and decreases renal glycolytic enzymes and
intermediates of the pentose phosphate pathway (86, 93). These observations
combined with the increased susceptibility to cisplatin-induced AKI suggested the
hypothesis that NHERF1 KO mice have metabolic alterations that predispose
them to cisplatin nephrotoxicity. Therefore, the goal of Chapter III was to define
metabolic changes in the NHERF1 KO mouse. Overall this study uncovered new
areas to investigate in understanding susceptibility to cisplatin-induced AKI with
NHERF1 loss.
NHERF1 KO mice did not exhibit changes in gluconeogenic or glycolytic
enzyme activity. Indeed, cisplatin treatment resulted in a parallel decrease in
FBPase and G6Pase activity in NHERF1 KO and WT mice. Additionally, there
were no significant changes with LDH and MDH activity between non-treated and
treated WT and NHERF1 KO mice. These results coincide with previous studies
(86, 94). NHERF1 KO mice also do not have changes in kidney ATP content
when compared to WT. On the other hand, NHERF1 KO mouse kidneys exhibit
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increased activity of ME and G6PD under baseline conditions when compared to
WT mouse kidneys. Cisplatin treatment resulted in a decrease in G6PD and ME
activity in the NHERF1 KO kidneys that was equivalent to the level of cisplatin
treated WT kidneys. These findings suggest that NHERF1 KO mice have
developed compensatory mechanisms involving the pentose phosphate pathway
and in NADPH production in order to maintain the cellular redox state. A similar
observation has been made in studies of liver cirrhosis in rats subject to oxidative
stress, where an increase in ME and G6PD gene expression and activity (164)
are also seen, presumably providing protection against the stress through an
increased production of NADPH (164).
These observations bring into question whether NHERF1 KO mice are under
oxidative stress that is masked due to increased NADPH. Therefore, when these
mice are given cisplatin, a known oxidative stress inducer, the mouse kidneys
undergo more severe damage due to the inability to combat the additional
underlying oxidative stress following cisplatin treatment. This work has revealed
new areas to investigate and laid the foundation for future studies, such as
investigating NADPH levels and gene and protein expression of ME and G6PD
between WT and NHERF1 KO mice.

2. Mechanism of susceptibility of NHERF1 KO mice to cisplatin-induced
AKI is not mitochondrial dysfunction
Chapter IV of this dissertation aimed to characterize any differences in
mitochondrial function and/or structure between WT and NHERF1 KO mice. This

107

aim builds upon the work described in Chapter III of this dissertation, which
demonstrated that NHERF1 KO mice do not have gluconeogenic or glycolytic
enzyme activity alterations, but do have increased pentose phosphate enzyme
activity. In addition to affecting metabolic pathways cisplatin nephrotoxicity has
been established in inducing apoptotic and necrotic cell death. The mechanisms
involved in cisplatin-induced nephrotoxic cell death remain unclear. However,
there is increasing evidence that ROS and mitochondrial function have an
important role in cisplatin’s mechanism of injury. As discussed in Chapter III,
NHERF1 KO mice may have increased levels of NADPH to maintain cellular
redox levels, therefore the results from Chapter III and previous studies from our
laboratory (poor survival of NHERF1 deficient OK cells and decreased
expression of mitochondrial BBM proteins in NHERF1 KO mice) suggested the
hypothesis that NHERF1 loss may be associated with mitochondrial dysfunction
and susceptibility to kidney injury.
In Chapter IV there were two main goals in characterizing differences in
mitochondria between WT and NHERF1 KO mice: [1] to determine if NHERF1
KO mice have altered mitochondrial function and/or structure and [2] to
determine NHERF1 KO mice have an underlying mitochondrial dysfunction and if
that predisposes these animals to cisplatin nephrotoxicity. EM analysis revealed
that NHERF1 KO mice have similar proximal tubule mitochondrial morphologies,
size, and distribution and number when compared to WT. Furthermore, there
were no overt signs of oxidative stress in NHERF1 KO mitochondria. In fact, only
early ischemic changes most likely due to harvesting were noted. In addition,
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isolated mitochondria from NHERF1 KO kidneys were found to have similar
oxidative capacities as demonstrated by nonsignificant changes in OCR and
similar RCR (WT: 1.63 and KO: 1.61) (Figure 4.3C) to those of WT mice. The
RCR data is compelling since this is the best general measure of mitochondrial
function in isolated mitochondria. RCR gives an idea into the mitochondria’s
ability to respond robustly to the addition of substrate and ADP through the
production of ATP. In addition, the RCR value is unique to each tissue and
substrate used (146). Therefore, NHERF1 KO mitochondria when isolated from
their environment function normally. This study answers an important aspect in
evaluating NHERF1 KO mitochondria which is that they can function normally
when given optimal components. However, this poses the question if NHERF1
KO mitochondria function normally in their natural environment. NHERF1 KO
mice undergo phosphate wasting (148) potentially creating an intracellular
environment where mitochondria cannot function properly. This work uncovers a
novel potential mechanism of susceptibility to cisplatin-induced AKI that can be
investigated in future studies. Seahorse XF24 analysis on kidney tissue would be
beneficial in establishing if NHERF1 KO mice have mitochondrial dysfunction due
to phosphate wasting that sensitizes the kidney to cisplatin toxicity.

3. NHERF1 loss affects GGT activity in response to cisplatin
The studies in Chapter III and Chapter IV focus on potential underlying
changes that could increase susceptibility to cisplatin nephrotoxicity. Therefore,
Chapter V focused on the renal handling of cisplatin between WT and NHERF1
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KO mice. This study was based on the hypothesis that NHERF1 loss results in
altered renal uptake and/or metabolism of cisplatin resulting in increased toxicity.
Understanding the renal handling of cisplatin is an important area of research
that has been substantially investigated. Unfortunately, many aspects of
cisplatin’s metabolism to a nephrotoxin remain ambiguous with conflicting results.
For example, the role of GGT activity in cisplatin nephrotoxicity is controversial,
where enhanced GGT activity may either increase or decrease sensitivity to
cisplatin-induced AKI (151). Furthermore, in the proposed hypothesis of
cisplatin’s biotransformation to a nephrotoxin, cisplatin is thought to exit the
proximal tubule via MATE1 where it is further processed in the tubular lumen and
taken up in the proximal tubule by an unknown transport protein. Thus, the
conflicting data along with potentially other unknown players add a degree of
complexity in understanding cisplatin-induced AKI.
Before investigating changes in renal handling of cisplatin, Chapter V first set
to establish that NHERF1 KO mice are indeed more sensitive to the initial
cisplatin insult. Therefore, WT and NHERF1 KO mice were treated with cisplatin
for 24 hours instead of 72 hours. These kidneys were processed for histology
and markers of kidney injury. Ultimately, NHERF1 KO mouse kidneys were
confirmed to be more sensitive to the initial insult, characterized by early
histologic changes (casts and BBM sloughing) along with significantly increased
urine NGAL protein when compared to cisplatin treated WT.
Next, levels of lipid peroxidation were assessed by the means of TBARS
analysis and IHC of 4-HNE between vehicle and cisplatin treated WT and
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NHERF1 KO mice. Some studies have shown that cisplatin induces lipid
peroxidation, and are thought to be involved in ROS induced cell death (165).
NHERF1 KO mouse kidneys were found to not have increased levels of lipid
peroxidation under baseline conditions, however, with cisplatin treatment IHC
analysis revealed increased positive staining for 4-HNE in the cortex and the JM
regions of the kidney. Even though there was no apparent increase in lipid
peroxidation other indicators of oxidative stress were measured. These indicators
included the oxidized and reduced forms of small molecular weight thiols that act
as antioxidants. Plasma from 72 hour cisplatin treated mice showed a decrease
in all reduced and oxidized forms of glutathione and cysteine which is consistent
with other reports (25, 158-160). The only difference noted between NHERF1 KO
mouse plasma and WT alone was a decrease in the oxidized form of cysteine,
CySS. CySS is necessary for the production of the cellular antioxidant GSH
(161). Interestingly, the kidney GSH levels of NHERF1 KO mice do not reflect the
decrease in plasma CySS. The decrease in CySSG and GSSG in the kidney
after cisplatin administration are consistent with other reports, however GSH
was, unexpectedly, not decreased in either genotype (159). Furthermore, the
oxidized form of glutathione, GSSG, was increased in the kidneys of vehicle
treated NHERF1 KO mice. In summary, NHERF1 KO mice had a decrease in
oxidized cysteine in the plasma, an increase in oxidized glutathione in the kidney,
and a decrease in kidney redox potential (GSH/GSSG) when compared to WT.
These results may indicate that NHERF1 KO kidneys are under a level of
oxidative stress and support the findings in Chapter III, where the pentose
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phosphate enzymes may be increased to compensate with a higher NADPH
production to maintain cellular redox levels. On the other hand, NHERF1 KO
kidneys do not have a decrease in GSH levels and appear to not have changes
in GSH metabolism itself.
Lastly, enzymes thought to be involved in cisplatin’s mechanism to a reactive
thiol were considered. GGT activity in the urine was found to be highest between
4 and 24 hours following cisplatin treatment in humans (154), indicating these
time points should be used in assessing differences in activity level. At 4 hours
GGT activity remained unvarying between the treatment groups. However, at 24
hours WT mouse kidneys responded to cisplatin treatment with a substantial
increase in activity while NHERF1 KO kidneys maintained a steady activity level.
These data indicate that NHERF1 KO mice respond differently to the cisplatin
insult. Whether this response is time dependent or based on functional ability of
the enzyme is unclear. A 12 hour time point may be helpful to further elucidate
the changes in GGT activity in treated NHERF1 KO mice. Interestingly, GGT
protein levels were unchanged between the treatment groups via western blot.
IHC was also performed on NHERF1 KO and WT kidneys resulting in similar
staining intensity and localization of GGT within the tubules under baseline
conditions. However, 24 hours after cisplatin treatment NHERF1 KO kidneys
began to show some histologic changes including BBM sloughing which
coincided with decreased staining for GGT. These data are consistent with other
studies performed on rats at 72 hours, where increased damage to the proximal
tubule coincided with decreased GGT expression and activity (116, 154, 163).
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Although NHERF1 KO kidney GGT protein expression remained insignificant
with cisplatin treatment it is apparent that the degree of injury at 24 hours is less
than what is seen at 72 hours. It is possible that NHERF1 KO mouse kidneys are
beginning to lose GGT at 24 hours through BBM sloughing, but have not lost a
significant amount of GGT protein at this time point. These experiments could be
repeated on 72 hour cisplatin treated mice for improved interpretation of these
results. CCBL protein was also measured in these mice. Similar to the GGT
western blot data CCBL protein remained insignificantly altered between the
different groups.
This study has provided some clarification regarding changes in the renal
handling of cisplatin with NHERF1 loss. The main finding being an altered
response in GGT activity with the cisplatin insult. Furthermore, this study
confirmed that NHERF1 KO mice are indeed more sensitive to the cisplatin
insult. NHERF1 KO mice do not have overt signs of oxidative stress, but this may
be masked by compensatory mechanisms in the pentose phosphate pathway.
Most importantly, this study has laid the groundwork for future experiments
regarding altered renal handling of cisplatin in the NHERF1 KO mouse. A few
examples include: implementing a 12 hour time point to study time dependent
changes in GGT activity following cisplatin treatment, CCBL activity and
localization, and evaluating GGT and CCBL localization and protein levels 72
hours after cisplatin treatment.

C. Significance of new findings
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Chapter III investigated metabolic changes in NHERF1 KO mice that may
predispose these animals to cisplatin nephrotoxicity. Moreover, gluconeogenic
and glycolytic enzymes were found to be unchanged, but ME and G6PD had
increased activities with NHERF1 loss. The significance of these findings is that
that NHERF1 KO mice may have compensatory mechanisms in the NADPHdependent processes for maintenance of the cellular redox state. G6PD and ME
are the two main sources of cytosolic NADPH, which is important for protection
from oxidative stress (166). Furthermore, G6PD activity through the generation of
ribose-5-phosphate is also involved in nucleic acid synthesis and repair (164).
Therefore, enhancement of ME and G6PD is consistent with the presence of
some underlying stress in the NHERF1 KO mouse. The combined effect of an
underlying oxidative stress and the cisplatin-induced oxidative stress could result
in increased sensitivity and exacerbation of injury with NHERF1 loss.
The work in Chapter IV involved characterizing differences in mitochondrial
structure and/or function between WT and NHERF1 KO kidneys. Interestingly, no
changes in mitochondrial structure, number or size were found to indicate an
altered function or mitochondrial oxidative stress. Furthermore, Seahorse XF24
functional assays determined that isolated NHERF1 mitochondria function
normally when compared to WT. This observation suggests that NHERF1 KO
mitochondria have normal bioenergetics when all required compounds are
available. However, NHERF1 KO mice do undergo phosphate wasting (148),
potentially creating a suboptimal intracellular environment for mitochondria.
Inorganic phosphate is essential for many cellular functions such as signal
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transduction and energy metabolism. For instance, inorganic phosphate uptake
into mitochondria is required for oxidative phosphorylation and the subsequent
production of ATP (167). Mitochondrial inorganic phosphate also activates matrix
enzymes and ETC activity (167). Moreover, in insulin secreting cells inorganic
phosphate uptake results in further hyperpolarization of the electrical gradient
(167). Therefore, the significance of this work is the formulation of a novel
potential mechanism of susceptibility to cisplatin-induced AKI. Thus, NHERF1
KO mice may have mitochondrial dysfunction due to phosphate wasting that
sensitizes the kidney to cisplatin toxicity. Seahorse XF24 functional analysis on
whole kidney tissue would be beneficial for future studies.
The biotransformation of cisplatin to a nephrotoxin is poorly understood and
the state of research in the field is encumbered with controversial results.
Therefore, more research is needed in this area for the development of future
therapies or early prognostic tests. In Chapter V changes in the renal handling of
cisplatin were investigated in the NHERF1 KO mouse. First, NHERF1 KO mice
were confirmed to have increased sensitivity to the initial cisplatin insult. This was
demonstrated by early histologic signs of damage in the NHERF1 KO kidney
when compared to WT. Additionally, urine NGAL was significantly increased in
the 24 hour cisplatin treated NHERF1 KO mouse in comparison to the WT.
Following that information, lipid peroxidation levels were assessed and found to
be minimal in vehicle treated WT and NHERF1 KO mice. However, the cisplatin
treated NHERF1 KO mouse had increased 4-HNE staining in the cortex and JM
regions when compared to WT. Reduced and oxidized forms of Cys and GSH
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were compared between WT and NHERF1 KO mice. Although there were some
differences in vehicle treated NHERF1 KO mice there were no overt signs of
oxidative stress. GSH levels remained unchanged in both WT and NHERF1 KO
animals, however, the kidney redox potential in the NHERF1 KO mouse was
significantly decreased when compared to WT. An increase in redox potential is
indicative of increased oxidative stress. However, with the increased activity in
G6PD and ME found in Chapter III, indicators of oxidative stress may be masked.
Thus, a decrease in redox potential may be a sign of compensatory mechanisms
to protect from oxidative stress. Finally, since GSH levels were unchanged
between WT and NHERF1 KO mice it appears the KO mouse has unaltered
GSH metabolism. In addition to the thiol measurements GGT activity, protein
level, and localization was also assessed. While the protein level was unchanged
between all treatment groups the GGT activity response was found to be altered
with cisplatin treatment in the KO mouse. GGT is important for detoxification of
xenobiotics and production of GSH, and thus, increased activity may alleviate
some of the induced oxidative stress from cisplatin. If an increase in GGT activity
is protective then the NHERF1 KO may not have the ability to increase GGT
activity quickly and/or robustly with the cisplatin insult, resulting in exacerbated
injury. Alternatively, if an increase in GGT activity is detrimental, then a 12 hour
time point may be useful in determining if GGT activity fluctuates over time.
Therefore, since the KO mouse already has kidney damage at 24 hours there
could be an increase in activity between 4 and 24 hours resulting in this early
injury. Another potential explanation for a lack of increase in GGT activity may be
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due to the histologic changes seen 24 hours after cisplatin treatment, where
NHERF1 KO mice have patchy areas of BBM sloughing resulting in GGT loss.
This hypothesis would coincide with data from other studies using 72 hour
cisplatin treated rats. When the rats exhibited increased damage to the proximal
tubule the damage corresponded with decreased GGT expression and activity
(116, 154, 163). Therefore, it is possible that NHERF1 KO mice are beginning to
lose GGT at 24 hours through BBM sloughing, but have not lost a significant
amount of GGT protein to be reflected in the western blot data. Finally, CCBL
protein was also considered in this study. Similar to the GGT protein there were
no significant changes in CCBL between any of the treatment groups. These
data provide insight into the effects of NHERF1 loss and renal handling of
cisplatin. Furthermore, this insight has contributed to upcoming experiments that
may lead to new hypotheses and therapeutic approaches in the study of
cisplatin-induced AKI.

D. Strengths and weaknesses of this dissertation
1. Strengths
There are several strengths of this dissertation. The first study provides
insight into the role of NHERF1 loss and metabolic changes in the pentose
phosphate pathway (Chapter III). The second study (Chapter IV) established that
NHERF1 KO mice isolated mitochondria do not have structural or functional
changes that would result in dysfunction. Lastly, Chapter V established that
NHERF1 KO mice are indeed sensitive to the initial cisplatin insult and have an
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altered GGT activity response when given cisplatin. Overall this dissertation
identifies that NHERF1 KO mice respond differently to the cisplatin insult.
Additionally, it provides novel hypotheses that could lead to potential therapeutic
approaches or prognostic tests for cisplatin-induced AKI. Currently, no FDA
approved therapy exists to halt or reverse cisplatin-induced AKI.
All the work in Chapters III and V was performed in the whole animal. Use of
the whole animal is particularly important when studying diseases and allows
better translation to human disease. Chapter IV utilized sensitive approaches in
establishing mitochondrial changes in the NHERF1 KO mouse. Additionally,
these studies used multiple time points with an established acute model of
cisplatin-induced AKI. Furthermore, pharmaceutical grade cisplatin was used
when treating the animals. While no model fully recapitulates the human disease,
this model provided an established result of nephrotoxicity in WT C57BL/6J mice.
Thus, the experimenter can determine changes in response to cisplatin in the
NHERF1 KO mice. Additionally, the mice used in these experiments were all
within the same age range (2-4 months old) and were littermates. These steps
were taken in order to ensure the animals used were young, healthy, and did not
have genetic drift that may affect the results of these studies.
The renal circadian clock is known to regulate the dosing-time dependency of
cisplatin-induced nephrotoxicity in mice (168). All of the mice used in this study
were treated with cisplatin at approximately 10 a.m. and sacrificed either 24 or 72
hours later. Unfortunately, the 4 hour time point was conducted earlier at 6 a.m.
due to restrictions in access to the mice. However, it was deemed to be more
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important to sacrifice all the animals at the same time point of 10 a.m. This
decision was made after extensive literature searches, where other studies found
that when mice were treated with cisplatin later in the day they exhibited less
kidney injury (169). Thus, this experimental design attempts to mitigate any
effects of circadian rhythms on cisplatin nephrotoxicity.
Experimental design is extremely important in mitigating factors that could
influence results. In addition to using established animal models of cisplatininduced AKI and taking into account circadian rhythm, most of these studies
used five or more animals in each treatment group. This number is due in part to
the increased sensitivity of the NHERF1 KO mouse to cisplatin and the variability
in kidney injury seen with cisplatin treatment. As previously mentioned these
studies also utilized highly sensitive methods for analysis. For instance, LC-MS
was utilized in order to determine the ATP content of WT and NHERF1 KO
kidneys. This method is very sensitive and is advantageous when compared to
commercially available kits used to measure ATP.

2. Weaknesses
The main purpose of this work was to investigate potential mechanisms of
susceptibility of the NHERF1 KO mouse to cisplatin nephrotoxicity. In order to
study the effects NHERF1 loss and its effect before and after cisplatin treatment,
WT C57BL/6J and C57BL/6J mice with a global deletion of NHERF1 were used.
Whole mouse deletions can result in non-specific effects due to compensatory
mechanisms that are selected for early in development. NHERF1 KO mice are
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viable, fertile, and histologically the kidneys are similar to WT. However,
NHERF1 KO mice do have alterations in kidney function, phosphate wasting, uric
acid wasting, and hypercalciuria (46). The potential roles of alterations in
electrolyte metabolism were not tested in this study.
Although there are strengths associated with the use of a mouse model, there
are also limitations. The use of in vivo experiments may recapitulate human
disease more completely when compared to in vitro experiments. Unfortunately,
the use of in vivo research also involves less control of variables and introduces
complexities. Furthermore, relevance to human disease may be questionable
when mouse models are compared to human studies. At this time the role of
NHERF1 loss and susceptibility to cisplatin nephrotoxicity has not been studied
in humans. It is therefore possible that NHERF1 loss is not detrimental or that the
observed changes in the pentose phosphate pathway and in GGT activity may
be mouse-specific and have little relevance to humans. While these aspects of in
vivo models can never be entirely avoided, it can be optimized for the question at
hand and taken into consideration when interpreting results.
Other limitations of this study involve the ambiguous and complex process of
cisplatin biotransformation in the kidney. The controversial role of GGT activity
has been extensively discussed in this dissertation. However, another limitation
in studying cisplatin metabolism involves CCBL. Mammals have at least 10
variations in CCBL, none of which have been conclusively linked with cisplatin
nephrotoxicity (170). However, glutamine transaminase K (GTK) has a high
inherent CCBL activity and therefore is the most studied in cisplatin
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nephrotoxicity. In this dissertation the antibody against CCBL1 or GTK was
utilized and future activity assays will also be performed using GTK. This added
complication is another limitation when studying the biotransformation of
cisplatin. Therefore, any results using GTK may not be relevant in mice let alone
human subjects.

E. Future Directions
While the experiments described in this dissertation answered specific gaps
in our knowledge of NHERF1 loss and susceptibility to cisplatin nephrotoxicity, it
has also created new questions that will need to be addressed in future studies.
Seven of these questions are discussed below.

1. Is the increased ME and G6PD activity identified in Chapter III a
compensatory mechanism to maintain the cellular redox state in
NHERF1 KO mice?
In Chapter III ME and G6PD activity was increased in the NHERF1 KO
mouse and suggested the possibility of increased NADPH production to provide
protection from oxidative stress. Therefore, measuring NADPH levels in the WT
and NHERF1 KO kidneys is necessary to answer this question. To carry out this
investigation LC-MS analysis would be the most sensitive method in measuring
NADPH levels. Additionally, ATP and NADPH could be measured in cisplatin
treated animals to further understand the bioenergetics of the NHERF1 KO
mouse in response to insult. In the previous study cisplatin treated NHERF1 KO

121

mice were found to have increased ATN (35), which may be indicative of
decreased ATP and/or NADPH levels. In addition, measuring gene and protein
expression of ME and G6PD could also be investigated to further understand any
compensatory mechanisms of the NHERF1 KO mouse.

2. Do the NHERF1 KO mitochondria function normally in whole tissue or
with changes in substrate?
In Chapter IV NHERF1 KO kidney mitochondria were found to function
normally in optimal conditions, however this does not answer how the
mitochondria function in their native environment. Fortunately, Agilent has
developed Seahorse XF24 islet capture microplates which can be used to
analyze whole tissue. Furthermore, there have been previous studies using this
method in multiple tissue types (171-173). Optimization will be needed for the
kidney, but whole tissue analysis will be useful in determining how NHERF1 KO
mitochondria function within the kidney. In addition to examining mitochondrial
function in the kidney, other substrates could be used besides
succinate/rotenone when assessing isolated mitochondrial function. Agilent also
has a palmitate-BSA fatty acid oxidation substrate that can be used to assess
fatty acid oxidation in isolated mitochondria. This consideration is of importance
as proximal renal tubules use fatty acids as their major source of energy.

3. Does cisplatin damage NHERF1 KO mitochondria to a greater degree
than WT mitochondria?
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Cisplatin has been established in inducing ROS and mitochondrial
dysfunction (139, 140, 142, 143). Furthermore, platinum can be found in
mitochondria 24 hours after cisplatin treatment. This information combined with
studies from Chapter IV gives rise to multiple future experiments. WT and
NHERF1 KO mice could be treated with cisplatin for 24 and 72 hours and
mitochondria can be isolated from these kidneys for Seahorse XF24 functional
analysis and measurement of platinum by inductively coupled plasma-mass
spectrometry (ICP-MS). Additionally, ROS could be measured in isolated
mitochondria using mitoSOX for mitochondrial O2 detection. These studies could
help in understanding if cisplatin is taken up to a greater degree in NHERF1 KO
mitochondria and if cisplatin damages these mitochondria to a greater degree
resulting in enhanced injury.

4. Does NHERF1 loss result in altered renal handling of cisplatin
besides GGT activity?
In addition to GGT activity CCBL activity can also be measured between
vehicle and cisplatin treated WT and NHERF1 KO mice. There are multiple
methods to assess CCBL activity, however GTK activity assay is simple and has
been well studied (174). Additionally, IHC can be utilized to assess CCBL
localization in vehicle and cisplatin treated WT and NHERF1 KO kidneys. ICPMS can also be used to measure platinum levels between cisplatin treated WT
and NHERF1 KO kidneys. An increase in platinum in the NHERF1 KO kidney
could indicate altered uptake or extrusion of cisplatin. Higher concentrations of
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cisplatin have been associated with increased necrotic cell death which was seen
in the 72 hour cisplatin treated NHERF1 KO mouse (35). Furthermore, WT and
NHERF1 KO mice could be treated with known inhibitors for OCT2, MATE1, and
GGT in order to determine if the KO mouse responds the same and exhibits
either amelioration or enhancement of toxicity. These outcomes could help to
identify key players in the susceptibility of the NHERF1 KO mouse to cisplatin
nephrotoxicity. Lastly, OK and NHERF1 deficient OK proximal tubule cells could
be used to overexpress GGT to evaluate the effect of increased GGT expression
on activity after treatment with cisplatin. This information would again, help to
elucidate if increased GGT activity is detrimental or protective with NHERF1 loss
and cisplatin treatment.

5. How do NHERF1 KO mice respond to a chronic model of cisplatin
nephrotoxicity?
Utilization of a chronic repeated dosing model of cisplatin nephrotoxicity could
help in determining if NHERF1 KO mice are only sensitive to an acute high dose
of cisplatin or if they are equally sensitive to lower repeated doses over time. In
WT mice the kidney damage associated with the chronic model is less severe
and results in longer survival (175). Studying NHERF1 loss and cisplatin
nephrotoxicity in a chronic model could provide information in understanding
conditions when NHERF1 loss is detrimental with cisplatin administration.

124

6. Do heterozygous NHERF1 KO mice have some protection to cisplatin
nephrotoxicity?
All of the studies mentioned in this dissertation have been conducted with
complete loss of the NHERF1 protein. To broaden our knowledge of
susceptibility to cisplatin nephrotoxicity with NHERF1 loss, heterozygous mice
could also be tested using the acute cisplatin model. This could help answer the
following questions: [1] is complete loss of NHERF1 expression needed for
susceptibility to cisplatin nephrotoxicity and [2] is there a percent loss of NHERF1
that predisposes these animals to cisplatin nephrotoxicity?

7. Does NHERF1 loss predispose mouse kidneys to other nephrotoxins
or forms of AKI?
These studies have only evaluated the nephrotoxic effects of cisplatin in
NHERF1 KO mice. It would be interesting to establish if these mice are only
sensitive to cisplatin or if other nephrotoxins also result in enhanced injury. For
example, cyclosporine, vancomycin, acyclovir, lead, mercury, and cadmium
could be tested. In addition, models of ischemic reperfusion could also be
evaluated.

F. Summary and conclusions
The overall goal of the work described in this dissertation was to discover new
potential mechanisms and hypotheses for susceptibility to cisplatin-induced AKI
with NHERF1 loss. Chapter III evaluated metabolic alterations in the NHERF1
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KO mouse that may play a role in the susceptibility to cisplatin insult. This study
provided the foundation for new hypotheses and future experiments concerning
changes in NADPH production in the NHERF1 KO mouse and masked signs of
oxidative stress that may predispose these animals to injury. Chapter IV aimed to
evaluate if NHERF1 KO mice had an underlying mitochondrial dysfunction due
to: [1] decreases in mitochondrial oxidative capacity and/or alterations in the
structure of NHERF1 KO kidneys [2] decreases in number of mitochondria in
NHERF1 KO kidney. This study did not find any evidence of mitochondrial
dysfunction in the NHERF1 KO mouse. Finally, Chapter V assessed if NHERF1
loss resulted in altered renal handling of cisplatin and found an altered GGT
activity response when NHERF1 KO mice were given cisplatin. Taken together,
these studies provide new insight into the mechanism of susceptibility of
NHERF1 loss in cisplatin-induced AKI.
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ABBREVIATIONS
ACEI

Angiotensin converting enzyme inhibitors

AGN

Acute glomerulonephritis

AIN

Acute interstitial nephritis

AKI

Acute kidney injury

ANOVA

Analysis of variance

AP

Aminopeptidase

ARB

Angiotensin receptor blockers

ATN

Acute tubular necrosis

ATPase

Adenosine triphosphatase

BBM

Brush border membrane

BCA

Bicinchoninic acid

BSA

Bovine serum albumin

BUN

Blood urea nitrogen

CCBL

Cysteine-S-conjugate beta lyase

CCBL1

Alternative name for glutamate transaminase k

CKD

Chronic kidney disease

CRAC

Cholesterol binding domain

Ctr1

Copper transporter 1

CySSG

Cysteine-glutathione disulfide

Cys

Cysteine

CySS

Cystine

CXCR2

C-X-C motif chemokine receptor 2

E. coli

Escherichia coli

EGFR

Epidermal growth factor receptor

EGTA

Ethylene glycol tetraacetic acid
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ELISA

Enzyme-linked immunosorbent assay

EM

Electron microscopy

EMT

Epithelial-mesenchymal-transition

ERM

Ezrin-radixin-moesin

ETC

Electron transport chain

FBPase

Fructose-1,6-bisphosphatase

FDA

Food and drug administration

GAPDH

Glyceraldehyde 3-phosphate dehydrogenase

GFR

Glomerular filtration rate

GGT

γ glutamyl transpeptidase or transferase

GI

Gastrointestinal

GPCRs

G-protein-coupled-receptors

GSH

Glutathione

GSSG

Glutathione disulfide

GTK

Glutamate transaminase k

G6Pase

Glucose-6-phosphatase

G6PD

Glucose-6-phosphate dehydrogenase

HEPES

4-(2-hydroxylethyl)-1-piperazineethanesulfonic acid

H&E

Hematoxylin and eosin

HPLC

High-performance-liquid-chromatography

IACUC

Institutional animal care and use committee

ICAM-1

Intracellular adhesion molecule 1

ICU

Intensive care unit

IHC

Immunohistochemistry

IL8

Interleukin 8

IP

Intraperitoneal

JM

Juxtamedullary

KO

Knock out

LC-MS

Liquid chromatography-mass spectrometry
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LDH

Lactate dehydrogenase

MATE1

Multidrug and toxin extrusion 1

MDA

Malondialdehyde

MDCK

Madrin-darby-canine-kidney

MDH

Malate dehydrogenase

MOPS

3-(N-morpholino)propanesulonic acid

mOsm/kg

Milliosmoles per kilogram

ME
NF-B

Malic enzyme
Nuclear factor kappa-light chain enhancer of activated B
cells

NGAL

Neutrophil gelatinase-associated lipocalin

NHERF1

Na/H exchange regulatory factor 1

NHE3

Sodium hydrogen antiporter 3

Nox1

NADPD oxidase

Npt2a

Sodium phosphate co-transporter type-2

NSAID

Nonsteroidal anti-inflammatory drug

OCR

Oxygen consumption rate

OCT2

Organic cation transporter 2

OK

Opossum kidney

PAS

Periodic acid-schiff

PBS
PDZ

Phosphate buffered saline
Post-synaptic density protein 95/drosophila discs
large/zonulaocculens-1

Pt

Platinum

PTH

Parathyroid hormone

RCR

Respiratory control ratio

ROCK

Rho-associated coiled-coil containing protein kinase

ROS

Reactive oxygen species

SEM

Standard error means

SNP

Single-nucleotide polymorphism

Stat3

Single transducer and activator of transcription 3
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TBARS

Thiobarbituric acid reactive substances

TCA

Trichloroacetic acid

TGF-β1

Transforming growth factor beta 1

TTBS

Tris-buffered saline with 0.5% Tween 20

WT

Wild type

VEGF

Vascular endothelial growth factor

4-HNE

4-hydroxylnonenal
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High School Student Summer Fellow
2008
Department of Biochemistry & Molecular Genetics, University of Louisville,
Louisville, KY
Mentor: James Wittliff, Ph.D.


Project: Comparing the effects of estrogen mimics and breast carcinoma.
AREAS OF RESEARCH EXPERTISE







Cisplatin nephrotoxicity
Acute kidney injury
In vivo models of kidney
injury
Urine exosome isolation
techniques
Primary proximal tubule cell
culture
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Mitochondrial isolation
techniques
Quantitative PCR
Tissue staining
Renal pathology

SKILLS






Proficient in Microsoft Office including Word, Excel, and PowerPoint
Experience with graphing and statistical analysis using GraphPad Prism
and SigmaPlot
Familiar with reference manager Endnote
Experience with IRB submissions (protocol, informed consent form, and
amendments)
Training in laboratory biorepository maintenance

ACADEMIC & PROFESSIONAL HONORS
Traineeships
 NIH R25 Cancer Education Program Trainee, 2013
 NIH R25 Cancer Education Program Trainee, 2012
 Institute for Molecular Diversity and Drug Design Program, 2012
 Summer Research Opportunities Program Trainee, 2011
Fellowships
 Integrated Program in Biomedical Sciences Fellowship, 2015-2017
Awards
 Finalist for the 2019 Research Louisville Pre-doctoral Graduate Student
Award at the University of Louisville’s Research Louisville Conference in
Louisville, KY
 Finalist for the 2019 American Physiological Society (APS) Renal Section
Pre-doctoral Award at Experimental Biology Conference in Orlando, FL
 Graduate Student Council Travel Award, 2019
 Finalist for the 2017 Cell and Molecular Physiological Society (CaMPS)
Robert Gunn Student Travel Award at Experimental Biology Conference in
Chicago, IL
 Class Representative, Department of Pharmacology and Toxicology,
University of Louisville, Louisville, KY (2015-2018)
 NCI Outstanding Cancer Research Presentation Award, 2012
Professional Societies
 American Society of Nephrology, 2016-present
 American Society for Pharmacology and Experimental Therapeutics,
2016-present
 University of Louisville Kidney Disease Program, 2015-present
 University of Louisville Science Policy and Outreach Group, 2015-present
Service to the Profession
07/2018

Collected clinical data for Superfund “Project Greenheart”

07/2018
Fellows

Led roundtable discussion for NCI R25 Cancer Education Program
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05/2018
Interviewed Ph.D. applicants for the Pharmacology and Toxicology
Department
01/2018

Volunteer science fair project judge at the National United States
Pony Clubs
Conference

05/2017
Interviewed Ph.D. applicants for the Pharmacology and Toxicology
Department
07/2016
Fellows

Led roundtable discussion for NCI R25 Cancer Education Program

05/2016
Interviewed Ph.D. applicants for the Pharmacology and Toxicology
Department
SELECTED ABSTRACTS & POSTER PRESENTATIONS
Local/Regional
1. Bushau-Sprinkle A., Watson W., Zheng Y., Gagnon K., Kitterman K.,
Barati M., Siskind L., Brier M., Lederer E. (2019) Mechanistic insight for
increased susceptibility to cisplatin nephrotoxicity with NHERF1 loss.
Research!Louisville Abs. #GRD-18, September 10-13, 2019, Louisville,
KY.
2. Bushau-Sprinkle A., Conklin C., Barati M., Dupre T., Gagnon K., Siskind
L., Doll M., Rane M., Clark B., Merchant M., Klinge C., Brier M., Coventry
S., Lederer E. (2018) NHERF1 loss results in metabolic stress and
increased susceptibility to cisplatin-induced acute kidney injury.
Research!Louisville Abs. #GRD-3, October 10-12, 2018, Louisville, KY.
3. Bushau-Sprinkle A. Dupre T., Siskind L., Sherwood A., Conklin C., Barati
M., Gagnon K., Khundmiri S., and Lederer E. (2016) The protective role of
NHERF1 in cisplatin-induced acute kidney injury. Research!Louisville Abs.
#GRM-3, October 11-13, 2016, Louisville, KY.
4. Sherwood A., Conklin C., Barati M., Gagnon K., Bushau-Sprinkle A.,
Merchant M., Lederer E., Khundmiri S. (2016) Mass spectrometry and
cellular bioenergetics analysis reveals altered mitochondrial function in the
kidneys of Na-H exchanger regulatory factor isoform 1 (NHERF1) deficient
mice. Research!Louisville Abs. #PRF-17, October 11-13, 2016, Louisville,
KY.
5. Sheehan R., Korte E., Bushau A., Powell D., Merchant M. (2015) ABIN1
ubiquitin binding regulates the proteome of exosomes derived from
podocytes. Research!Louisville. Louisville, KY.
6. Bushau A., Anders L., Douglas A., Joshi-Barve S., Poole L., Massey V.,
Falkner K., Cave M., McClain C., and Beier J. (2014) Mechanistic insight
into vinyl chloride-induced liver injury. Ohio Valley Society of Toxicology
(OVSOT) Annual Meeting, Dayton, OH.
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7. Bushau A., Andres S., and Wittliff J. (2013) Gene expression in breast
carcinomas from patients with ethnical differences. Research!Louisville,
Louisville, KY (National Cancer Institute Outstanding Cancer Research
Award)
8. Bushau A., and Hu C. The effects of chemo preventative food
components and dynasore (dynamin inhibitor) on β-1 integrin trafficking
and cell proliferation in pancreatic cancer cells. (2011) The University of
Louisville’s Summer Research Opportunity Poster Session, Louisville, KY.
National/International
1. Bushau-Sprinkle A., Conklin C., Barati M., Dupre T., Gagnon K., Siskind
L., Doll M., Rane M., Clark B., Merchant M., Klinge C., Brier M., Coventry
S., Lederer E. (2019) NHERF1 loss results in metabolic stress and
increased susceptibility to cisplatin-induced acute kidney injury. (2019)
Experimental Biology Annual Meeting Abs. #3438, April 6-9, 2019,
Orlando, FL.
2. Bushau-Sprinkle A., Conklin C., Barati M., Brier M., Coventry S., Dupre
T., Siskind L., Rane M., and Lederer E. (2017) NHERF1 deficiency
increases susceptibility to cisplatin-induced acute kidney injury. American
Society of Nephrology Kidney Week Abs. #TH-PO306, November 1-5,
2017, New Orleans, LA.
3. Bushau-Sprinkle A., Sherwood A., Conklin C., Barati M., Dupre T.,
Siskind L., Gagnon K., Khundmiri S., and Lederer E. (2017) The protective
role of NHERF1 in cisplatin-induced acute kidney injury. Experimental
Biology Annual Meeting Abs. #7605, April 22-26, 2017, Chicago, IL.
4. Anders L., Yeo H., Kaelin B., Bushau A., Lang A., Arteel G., McClain C.
and Beier J. (2016) Role of dietary fatty acids in liver injury caused by vinyl
chloride metabolites in mice. Hepatology 64:769A. (Presidential Poster of
Distinction).
5. Sherwood A., Khundmiri S., Conklin C., Siskind L., Bushau A., Dupre T.,
Barati M., Merchant M., Lederer E. (2016) Increased susceptibility to
cisplatin-induced acute kidney injury in the kidneys of Na-H exchanger
regulatory factor isoform 1 deficient mice. Experimental Biology Annual
Meeting, Abs. #B170, April 2-6, 2016, San Diego, CA.
6. Bushau A., Anders L., Douglas A., Joshi-Barve S., Poole L., Massey V.,
Falkner K., Cave M., McClain C., and Beier J. Mechanistic insight into
vinyl chloride-induced liver injury. Society of Toxicology Annual Meeting,
Abs. #125, March 22-26, 2015, San Diego, CA.
7. Anders L., Douglas A. Bushau A., Falkner K., Arteel G., Cave M.,
McClain C. and Beier J. (2014) Exposure to vinyl chloride metabolites
exacerbates liver injury caused by high fat diet in mice. Hepatology
60(1):719A. (Presidential Poster Distinction)
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PUBLICATIONS
1. Bushau-Sprinkle A. and Lederer E. New roles of the Na+/H+ exchange
regulatory factor 1 scaffolding protein: a mini review. AJP Renal. 2019
(under review)
2. Bushau-Sprinkle A. and Andres S.A. Effects of inflatable air vests and
prevention in equestrian injuries. (in progress)
3. Bushau-Sprinkle A., Barati M., Conklin C., Dupre, T., Gagnon K.,
Khundmiri, S., Clark B., Siskind L., Doll M., Rane M., Brier M., Coventry
S., Lederer E. Loss of the Na+/H+ exchange regulatory factor 1 increases
susceptibility to cisplatin-induced AKI. Am. J. Pathol. 2019 June;
159(6):1190-1200.
4. Andres S., Bushau-Sprinkle A., Brier M., and Seger Y. Effects of body
protection vests and experience levels in prevention of equestrian injuries.
BMJ Open Sport & Exercise Medicine. 2018; 4:e000426. Doi: 10.1136/
5. Anders L., Lang A., Anwar A., Douglas A., Bushau A., Falkner K., Hill B.,
Warner N., Arteel G., Cave M., McClain C., and Beier J. Vinyl chloride
metabolites potentiate inflammatory liver injury caused by LPS in mice.
Toxicol. Sci. 2016 June 8;151(2):312-23.
6. Anders L., Yeo H., Kaelin B., Lang A., Bushau, A., Douglas A., Cave M.,
Arteel G., McClain C., and Beier J. Role of dietary fatty acids in liver injury
caused by vinyl chloride metabolites in mice. Toxicol Appl Pharmacol.
2016 Sep 28.
PRESENTATIONS
1. Oral Presentation, 09/19, NHERF1: more than an anchor. University of
Louisville, Pharmacology and Toxicology Departmental Seminar,
Louisville, KY.
2. Poster Presentation Competition, 09/19, Mechanistic insight for increased
susceptibility to cisplatin nephrotoxicity with NHERF1 loss (3rd place
poster). University of Louisville’s Research!Louisville, Louisville, KY.
3. Poster Presentation Competition, 04/19, NHERF1 loss results in metabolic
stress and increased susceptibility to cisplatin-induced acute kidney injury
(3rd place poster). American Physiological Society Posters with Professors
Event at the Experimental Biology Annual Meeting, Orlando, FL.
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4. Poster, 04/19, NHERF1 loss results in metabolic stress and increased
susceptibility to cisplatin-induced acute kidney injury. Experimental
Biology Annual Meeting, Orlando, FL,
5. Poster, 10/18, NHERF1 loss results in metabolic stress and increased
susceptibility to cisplatin-induced acute kidney injury. University of
Louisville’s Research!Louisville, Louisville, KY.
6. Master’s Defense and Ph.D. Proposal, 12/17, Loss of the Na +/H+
exchange regulatory factor 1 results in increased susceptibility to cisplatininduced acute kidney injury. University of Louisville, Pharmacology &
Toxicology Departmental Seminar, Louisville, KY.
7. Poster, 11/17, NHERF1 deficiency increases susceptibility to cisplatininduced acute kidney injury. American Society of Nephrology Kidney
Week, New Orleans, LA.
8. Oral Presentation, 04/17, The protective role of NHERF1 in cisplatininduced acute kidney injury. Experimental Biology Annual Meeting,
Session: New Insights into Renal Transport: Application of Genetic Models
(Featured Topic), Chicago, IL.
9. Poster, 04/17, The protective role of NHERF1 in cisplatin-induced acute
kidney injury. Experimental Biology Annual Meeting, Chicago, IL.
10. Poster Presentation Competition, 04/17, The protective role of NHERF1 in
cisplatin-induced acute kidney injury. Cell and Molecular Physiological
Society session at the Experimental Biology Annual Meeting, Chicago, IL.
11. Poster, 10/16, The protective role of NHERF1 in cisplatin-induced acute
kidney injury. University of Louisville’s Research!Louisville, Louisville, KY.
12. Research Seminar, 04/16, The protective role of NHERF1 in cisplatininduced acute kidney injury. University of Louisville, Pharmacology &
Toxicology Department Seminar, Louisville, KY.
13. Poster, 03/15, Mechanistic insight into vinyl chloride-induced liver injury.
Society of Toxicology Annual Meeting, San Diego, CA.
14. Poster, 10/14 Mechanistic insight into vinyl chloride-induced liver injury.
Ohio Valley Society of Toxicology (OVSOT) Annual Meeting, Dayton, OH.
15. Poster, 04/13, Gene expression in breast carcinomas from patients with
ethnical differences (National Cancer Institute Outstanding Cancer
Research Presentation). University of Louisville, Research!Louisville,
Louisville, KY.
16. Poster, 08/11, The effects of chemo preventative food components and
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dynasore (dynamin inhibitor) on β-1 integrin trafficking and cell
proliferation in pancreatic cancer cells. The University of Louisville’s
Summer Research Opportunity Poster Session, Louisville, KY.
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